PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33276416-0	2021	Hippocampal hyperglutamatergic signaling matters: Early targeting glutamate neurotransmission as a preventive strategy in Alzheimer"s disease: An Editorial Highlight for "Riluzole attenuates glutamatergic tone and cognitive decline in AbetaPP/PS1 mice" on https://doi.org/10.1111/jnc.15224.	Riluzole	171-179	amyloid beta (A4) precursor protein	Mus musculus	235-242
33107040-0	2021	Riluzole Attenuates Glutamatergic Tone and Cognitive Decline in AbetaPP/PS1 Mice.	Riluzole	0-8	histocompatibility 2, class II antigen A, beta 1	Mus musculus	64-71
33722592-0	2021	Riluzole inhibits Kv4.2 channels acting on the closed and closed inactivated states.	Riluzole	0-8	potassium voltage-gated channel subfamily D member 2	Homo sapiens	18-23
33722592-4	2021	Here, we investigated the effects of riluzole on Kv4.2 channels transiently expressed in HEK-293 cells.	Riluzole	37-45	potassium voltage-gated channel subfamily D member 2	Homo sapiens	49-54
33722592-5	2021	Riluzole inhibited Kv4.2 channels with an IC50 of 190 +- 14 muM and the effect was voltage- and frequency-independent.	Riluzole	0-8	potassium voltage-gated channel subfamily D member 2	Homo sapiens	19-24
33722592-7	2021	When Kv4.2 channels were maintained at the closed state, riluzole incubation induced a tonic current inhibition.	Riluzole	57-65	potassium voltage-gated channel subfamily D member 2	Homo sapiens	5-10
33722592-10	2021	Altogether, our findings indicate that riluzole inhibits Kv4.2 channels mainly affecting the closed and closed-inactivated states.	Riluzole	39-47	potassium voltage-gated channel subfamily D member 2	Homo sapiens	57-62
33450052-7	2021	EXPERIMENTAL APPROACH: Patch-clamp experiments with ultra-fast solution exchange and photolabeling-coupled electrophysiology were applied to describe the unique mechanism of riluzole on Nav1.4 sodium channels.	Riluzole	174-182	sodium voltage-gated channel alpha subunit 4	Homo sapiens	186-192
33276416-0	2021	Hippocampal hyperglutamatergic signaling matters: Early targeting glutamate neurotransmission as a preventive strategy in Alzheimer"s disease: An Editorial Highlight for "Riluzole attenuates glutamatergic tone and cognitive decline in AbetaPP/PS1 mice" on https://doi.org/10.1111/jnc.15224.	Riluzole	171-179	presenilin 1	Mus musculus	243-246
33107040-0	2021	Riluzole Attenuates Glutamatergic Tone and Cognitive Decline in AbetaPP/PS1 Mice.	Riluzole	0-8	presenilin 1	Mus musculus	72-75
33107040-2	2021	Here, we evaluate 2-Amino-6-(trifluoromethoxy) benzothiazole (riluzole) as an early intervention strategy for AD, aimed at restoring glutamate neurotransmission prior to substantial Abeta plaque accumulation and cognitive decline.	Riluzole	18-60	histocompatibility 2, class II antigen A, beta 1	Mus musculus	182-187
33107040-2	2021	Here, we evaluate 2-Amino-6-(trifluoromethoxy) benzothiazole (riluzole) as an early intervention strategy for AD, aimed at restoring glutamate neurotransmission prior to substantial Abeta plaque accumulation and cognitive decline.	Riluzole	62-70	histocompatibility 2, class II antigen A, beta 1	Mus musculus	182-187
33107040-5	2021	Four months of prodromal riluzole treatment in AbetaPP/PS1 mice resulted in long-lasting procognitive effects and attenuated glutamatergic tone that was observed six months after discontinuing riluzole treatment.	Riluzole	25-33	histocompatibility 2, class II antigen A, beta 1	Mus musculus	47-54
33276416-1	2021	This Editorial highlights a remarkable study in the current issue of the Journal of Neurochemistry in which Huscup and coworkers provide novel data showing that riluzole, an anti-glutamatergic drug, may be a promising early intervention strategy for Alzheimer"s disease (AD), aimed at restoring glutamate neurotransmission prior to amyloid beta (Abeta) plaque accumulation and cognitive decline.	Riluzole	161-169	amyloid beta (A4) precursor protein	Mus musculus	346-351
33107040-5	2021	Four months of prodromal riluzole treatment in AbetaPP/PS1 mice resulted in long-lasting procognitive effects and attenuated glutamatergic tone that was observed six months after discontinuing riluzole treatment.	Riluzole	25-33	presenilin 1	Mus musculus	55-58
33107040-6	2021	Riluzole-treated AbetaPP/PS1 mice had significant improvement in long-term memory compared to vehicle-treated AbetaPP/PS1 mice that was similar to normal aging C57BL/6J control mice.	Riluzole	0-8	histocompatibility 2, class II antigen A, beta 1	Mus musculus	17-24
33385031-4	2021	The effect of the latter was tested after KCa3.1 channels were activated by riluzole 10 microM.	Riluzole	76-84	potassium calcium-activated channel subfamily N member 4	Homo sapiens	42-48
33107040-6	2021	Riluzole-treated AbetaPP/PS1 mice had significant improvement in long-term memory compared to vehicle-treated AbetaPP/PS1 mice that was similar to normal aging C57BL/6J control mice.	Riluzole	0-8	presenilin 1	Mus musculus	25-28
33107040-7	2021	Further, basal glutamate concentration and evoked-glutamate release levels, which were elevated in vehicle-treated AbetaPP/PS1 mice, were restored to levels observed in age-matched C57BL/6J mice in AbetaPP/PS1 mice receiving prodromal riluzole treatment.	Riluzole	235-243	histocompatibility 2, class II antigen A, beta 1	Mus musculus	115-122
33107040-7	2021	Further, basal glutamate concentration and evoked-glutamate release levels, which were elevated in vehicle-treated AbetaPP/PS1 mice, were restored to levels observed in age-matched C57BL/6J mice in AbetaPP/PS1 mice receiving prodromal riluzole treatment.	Riluzole	235-243	presenilin 1	Mus musculus	123-126
33107040-7	2021	Further, basal glutamate concentration and evoked-glutamate release levels, which were elevated in vehicle-treated AbetaPP/PS1 mice, were restored to levels observed in age-matched C57BL/6J mice in AbetaPP/PS1 mice receiving prodromal riluzole treatment.	Riluzole	235-243	histocompatibility 2, class II antigen A, beta 1	Mus musculus	198-205
31855905-2	2020	Earlier, we demonstrated the accumulation of phosphorylated histone H2AX (gammaH2AX), a marker for DNA damage when mGluR1-expressing melanoma cells were treated with a functional inhibitor, riluzole.	Riluzole	190-198	H2A.X variant histone	Homo sapiens	68-72
32926338-0	2020	Correction to: Fluoxetine and Riluzole Mitigates Manganese-Induced Disruption of Glutamate Transporters and Excitotoxicity via Ephrin-A3/GLAST-GLT-1/Glu Signaling Pathway in Striatum of Mice.	Riluzole	30-38	ephrin A3	Mus musculus	127-136
32926338-0	2020	Correction to: Fluoxetine and Riluzole Mitigates Manganese-Induced Disruption of Glutamate Transporters and Excitotoxicity via Ephrin-A3/GLAST-GLT-1/Glu Signaling Pathway in Striatum of Mice.	Riluzole	30-38	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	137-142
32926338-0	2020	Correction to: Fluoxetine and Riluzole Mitigates Manganese-Induced Disruption of Glutamate Transporters and Excitotoxicity via Ephrin-A3/GLAST-GLT-1/Glu Signaling Pathway in Striatum of Mice.	Riluzole	30-38	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	143-148
32891672-6	2020	Contrarily, after inhibiting Ca2+ influx with EGTA, riluzole alone and in combination with curcumin significantly downregulated hypoxia-induced expression of GFAP and NF-H.	Riluzole	52-60	glial fibrillary acidic protein	Homo sapiens	158-162
32891672-6	2020	Contrarily, after inhibiting Ca2+ influx with EGTA, riluzole alone and in combination with curcumin significantly downregulated hypoxia-induced expression of GFAP and NF-H.	Riluzole	52-60	neurofilament heavy chain	Homo sapiens	167-171
32891672-7	2020	After analysis of caspase 9 and cleaved caspase 9, we observed that curcumin and riluzole both inhibit apoptosis significantly, whereas their combination remains ineffective.	Riluzole	81-89	caspase 9	Homo sapiens	18-27
32891672-7	2020	After analysis of caspase 9 and cleaved caspase 9, we observed that curcumin and riluzole both inhibit apoptosis significantly, whereas their combination remains ineffective.	Riluzole	81-89	caspase 9	Homo sapiens	40-49
32891672-8	2020	Furthermore, we observed that neuroprotective effects of curcumin and riluzole are mediated through Nrf2/HO-1 signaling.	Riluzole	70-78	NFE2 like bZIP transcription factor 2	Homo sapiens	100-104
32891672-8	2020	Furthermore, we observed that neuroprotective effects of curcumin and riluzole are mediated through Nrf2/HO-1 signaling.	Riluzole	70-78	heme oxygenase 1	Homo sapiens	105-109
32304618-7	2020	It was concluded (i) that riluzole and ranolazine have anti-invasive effects on rat PCa cells and (ii) that Nav1.7 mRNA and protein expression can be modulated by riluzole under hypoxia.	Riluzole	163-171	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	108-114
32968789-17	2020	An additional patient with a SCN8A variant in domain IV of Nav1.6 (p.V1757>I) had a dramatic reduction in seizure frequency for several months after starting riluzole treatment, but then seizures recurred.	Riluzole	158-166	sodium voltage-gated channel alpha subunit 8	Homo sapiens	29-34
32968789-17	2020	An additional patient with a SCN8A variant in domain IV of Nav1.6 (p.V1757>I) had a dramatic reduction in seizure frequency for several months after starting riluzole treatment, but then seizures recurred.	Riluzole	158-166	sodium voltage-gated channel alpha subunit 8	Homo sapiens	59-65
32417392-5	2020	Moreover, knockdown of OR3A4 inactivated Wnt/beta-catenin signaling pathway, and Riluzole treatment could partially rescue the inhibitive effect of OR3A4 silencing on DLBCL cell proliferation.	Riluzole	81-89	olfactory receptor family 3 subfamily A member 4 pseudogene	Homo sapiens	148-153
32417392-8	2020	Finally, rescue assays confirmed that OR3A4 overexpression or the treatment of Riluzole could partially countervail the inhibitive effect of FOXM1 silencing on DLBCL progression.	Riluzole	79-87	forkhead box M1	Homo sapiens	141-146
32472497-0	2020	Fluoxetine and Riluzole Mitigates Manganese-Induced Disruption of Glutamate Transporters and Excitotoxicity via Ephrin-A3/GLAST-GLT-1/Glu Signaling Pathway in Striatum of Mice.	Riluzole	15-23	ephrin A3	Mus musculus	112-121
32472497-0	2020	Fluoxetine and Riluzole Mitigates Manganese-Induced Disruption of Glutamate Transporters and Excitotoxicity via Ephrin-A3/GLAST-GLT-1/Glu Signaling Pathway in Striatum of Mice.	Riluzole	15-23	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	122-127
32472497-0	2020	Fluoxetine and Riluzole Mitigates Manganese-Induced Disruption of Glutamate Transporters and Excitotoxicity via Ephrin-A3/GLAST-GLT-1/Glu Signaling Pathway in Striatum of Mice.	Riluzole	15-23	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	128-133
32472497-8	2020	Secondly, we found that astrocytes and mice pretreated with fluoxetine (100 muM or 15 mg/kg) and riluzole (100 muM or 32 mumol/kg) prior to Mn exposure had lower ephrin-A3 and Glu levels, but higher Na+-K+ ATPase activity, expression levels of GLAST and GLT-1 than those exposed to 500 muM or 50 mg/kg MnCl2.	Riluzole	97-105	ephrin A3	Mus musculus	162-171
32472497-8	2020	Secondly, we found that astrocytes and mice pretreated with fluoxetine (100 muM or 15 mg/kg) and riluzole (100 muM or 32 mumol/kg) prior to Mn exposure had lower ephrin-A3 and Glu levels, but higher Na+-K+ ATPase activity, expression levels of GLAST and GLT-1 than those exposed to 500 muM or 50 mg/kg MnCl2.	Riluzole	97-105	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	244-249
32472497-8	2020	Secondly, we found that astrocytes and mice pretreated with fluoxetine (100 muM or 15 mg/kg) and riluzole (100 muM or 32 mumol/kg) prior to Mn exposure had lower ephrin-A3 and Glu levels, but higher Na+-K+ ATPase activity, expression levels of GLAST and GLT-1 than those exposed to 500 muM or 50 mg/kg MnCl2.	Riluzole	97-105	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	254-259
31855905-2	2020	Earlier, we demonstrated the accumulation of phosphorylated histone H2AX (gammaH2AX), a marker for DNA damage when mGluR1-expressing melanoma cells were treated with a functional inhibitor, riluzole.	Riluzole	190-198	glutamate metabotropic receptor 1	Homo sapiens	115-121
31855905-5	2020	Using flow cytometry and a fluorescent antibody to gamma H2AX, our results demonstrate that NHEJ is likely to be the preferred DNA repair pathway to restore DNA double-stranded breaks induced by riluzole in mGluR1-expressing melanoma cells.	Riluzole	195-203	H2A.X variant histone	Homo sapiens	57-61
31855905-5	2020	Using flow cytometry and a fluorescent antibody to gamma H2AX, our results demonstrate that NHEJ is likely to be the preferred DNA repair pathway to restore DNA double-stranded breaks induced by riluzole in mGluR1-expressing melanoma cells.	Riluzole	195-203	glutamate metabotropic receptor 1	Homo sapiens	207-213
32168477-7	2020	They tested the effect of riluzole on MGMT, a DNA repair enzyme causing chemoresistance to TMZ, through quantitative real-time reverse transcription polymerase chain reaction in T98G cells.	Riluzole	26-34	O-6-methylguanine-DNA methyltransferase	Homo sapiens	38-42
32057920-10	2020	Riluzole-treated rats also developed smaller spinal cavities, showed higher levels of myelin basic protein (MBP) and neurofilament (NF)200 immunoreactivities, and lower levels of proinflammatory cytokines in the spinal cord at 7 days post-SCI.	Riluzole	0-8	myelin basic protein	Rattus norvegicus	86-106
32057920-10	2020	Riluzole-treated rats also developed smaller spinal cavities, showed higher levels of myelin basic protein (MBP) and neurofilament (NF)200 immunoreactivities, and lower levels of proinflammatory cytokines in the spinal cord at 7 days post-SCI.	Riluzole	0-8	myelin basic protein	Rattus norvegicus	108-111
32168477-0	2020	Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.	Riluzole	0-8	O-6-methylguanine-DNA methyltransferase	Mus musculus	75-79
32168477-10	2020	Riluzole enhanced the antitumor effect of TMZ synergistically in MGMT-positive but not in MGMT-negative GBM cell lines.	Riluzole	0-8	O-6-methylguanine-DNA methyltransferase	Mus musculus	65-69
32168477-2	2020	Riluzole, a metabotropic glutamate receptor 1 inhibitor, reportedly suppresses GBM growth.	Riluzole	0-8	glutamate receptor, metabotropic 1	Mus musculus	12-45
32168477-11	2020	Riluzole singularly suppressed MGMT expression, and it significantly suppressed TMZ-induced MGMT upregulation (p < 0.01).	Riluzole	0-8	O-6-methylguanine-DNA methyltransferase	Mus musculus	31-35
32168477-11	2020	Riluzole singularly suppressed MGMT expression, and it significantly suppressed TMZ-induced MGMT upregulation (p < 0.01).	Riluzole	0-8	O-6-methylguanine-DNA methyltransferase	Mus musculus	92-96
32168477-12	2020	Furthermore, combinatorial TMZ/riluzole treatment significantly suppressed tumor growth in the intracranial MGMT-positive GBM model (p < 0.05).	Riluzole	31-39	O-6-methylguanine-DNA methyltransferase	Mus musculus	108-112
32168477-13	2020	CONCLUSIONS: Riluzole attenuates TMZ-induced MGMT upregulation and enhances the antitumor effect of TMZ in MGMT-positive GBMs.	Riluzole	13-21	O-6-methylguanine-DNA methyltransferase	Mus musculus	45-49
32168477-13	2020	CONCLUSIONS: Riluzole attenuates TMZ-induced MGMT upregulation and enhances the antitumor effect of TMZ in MGMT-positive GBMs.	Riluzole	13-21	O-6-methylguanine-DNA methyltransferase	Mus musculus	107-111
32168477-14	2020	Therefore, combinatorial TMZ/riluzole treatment is a potentially promising novel therapeutic regimen for MGMT-positive GBMs.	Riluzole	29-37	O-6-methylguanine-DNA methyltransferase	Mus musculus	105-109
32057274-1	2020	Purpose: The objective of the research undertaken was to develop the Riluzole (RIZ) nanoparticles drug delivery system using Transferrin (Tf) as a ligand in the brain.Method: RIZ loaded chitosan nanoparticles and RIZ-Tf chitosan (CS) nanoparticles (RIZ CSNPs and RIZ-Tf CSNPs respectively) were formulated and compared for particles size, size distribution, encapsulation efficiency and surface morphology respectively.	Riluzole	69-77	transferrin	Homo sapiens	125-136
32231713-0	2020	Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway.	Riluzole	0-8	ATM serine/threonine kinase	Homo sapiens	97-100
32231713-0	2020	Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway.	Riluzole	0-8	tumor protein p53	Homo sapiens	101-104
32231713-9	2020	P53 silencing reduced cell reactiveness to riluzole therapy.	Riluzole	43-51	tumor protein p53	Homo sapiens	0-3
32231713-10	2020	These observations demonstrate that the riluzole-activated ATM/P53 pathway is directly involved in radiation-induced apoptosis of NPC cells.	Riluzole	40-48	ATM serine/threonine kinase	Homo sapiens	59-62
32231713-10	2020	These observations demonstrate that the riluzole-activated ATM/P53 pathway is directly involved in radiation-induced apoptosis of NPC cells.	Riluzole	40-48	tumor protein p53	Homo sapiens	63-66
32057274-1	2020	Purpose: The objective of the research undertaken was to develop the Riluzole (RIZ) nanoparticles drug delivery system using Transferrin (Tf) as a ligand in the brain.Method: RIZ loaded chitosan nanoparticles and RIZ-Tf chitosan (CS) nanoparticles (RIZ CSNPs and RIZ-Tf CSNPs respectively) were formulated and compared for particles size, size distribution, encapsulation efficiency and surface morphology respectively.	Riluzole	79-82	transferrin	Homo sapiens	125-136
32057274-1	2020	Purpose: The objective of the research undertaken was to develop the Riluzole (RIZ) nanoparticles drug delivery system using Transferrin (Tf) as a ligand in the brain.Method: RIZ loaded chitosan nanoparticles and RIZ-Tf chitosan (CS) nanoparticles (RIZ CSNPs and RIZ-Tf CSNPs respectively) were formulated and compared for particles size, size distribution, encapsulation efficiency and surface morphology respectively.	Riluzole	175-178	transferrin	Homo sapiens	125-136
32057274-1	2020	Purpose: The objective of the research undertaken was to develop the Riluzole (RIZ) nanoparticles drug delivery system using Transferrin (Tf) as a ligand in the brain.Method: RIZ loaded chitosan nanoparticles and RIZ-Tf chitosan (CS) nanoparticles (RIZ CSNPs and RIZ-Tf CSNPs respectively) were formulated and compared for particles size, size distribution, encapsulation efficiency and surface morphology respectively.	Riluzole	175-178	transferrin	Homo sapiens	125-136
32057274-1	2020	Purpose: The objective of the research undertaken was to develop the Riluzole (RIZ) nanoparticles drug delivery system using Transferrin (Tf) as a ligand in the brain.Method: RIZ loaded chitosan nanoparticles and RIZ-Tf chitosan (CS) nanoparticles (RIZ CSNPs and RIZ-Tf CSNPs respectively) were formulated and compared for particles size, size distribution, encapsulation efficiency and surface morphology respectively.	Riluzole	175-178	transferrin	Homo sapiens	125-136
32057274-1	2020	Purpose: The objective of the research undertaken was to develop the Riluzole (RIZ) nanoparticles drug delivery system using Transferrin (Tf) as a ligand in the brain.Method: RIZ loaded chitosan nanoparticles and RIZ-Tf chitosan (CS) nanoparticles (RIZ CSNPs and RIZ-Tf CSNPs respectively) were formulated and compared for particles size, size distribution, encapsulation efficiency and surface morphology respectively.	Riluzole	175-178	transferrin	Homo sapiens	125-136
31948038-0	2020	Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma.	Riluzole	25-33	mechanistic target of rapamycin kinase	Mus musculus	58-62
32035419-0	2020	Riluzole: a therapeutic strategy in Alzheimer"s disease by targeting the WNT/beta-catenin pathway.	Riluzole	0-8	catenin beta 1	Homo sapiens	77-89
32035419-12	2020	The focus of our review is to highlight the potential action of Riluzole in AD by targeting the canonical WNT/beta-catenin pathway to modulate glutamatergic pathway, oxidative stress and neuroinflammation.	Riluzole	64-72	catenin beta 1	Homo sapiens	110-122
31936257-8	2020	We report here that BK reduces spike frequency adaptation (SFA), inhibits the riluzole-activated current (IRIL), which flows mainly through TREK-2 channels, by about 45%, and reduces the open probability of identified single TREK-2 channels in cultured mSCG cells.	Riluzole	78-86	potassium channel, subfamily K, member 10	Mus musculus	140-146
31948038-3	2020	Here we report the identification of riluzole (Rilutek ), an FDA-approved drug for amyotrophic lateral sclerosis (ALS), via an in silico docking analysis of FDA-approved compounds, as an inhibitor of hnRNP A1.	Riluzole	37-45	heterogeneous nuclear ribonucleoprotein A1	Mus musculus	200-208
31948038-4	2020	In a riluzole-bead coupled binding assay and in surface plasmon resonance imaging analyses, riluzole was found to directly bind to hnRNP A1 and inhibited IRES activity via effects on ITAF/RNA-binding.	Riluzole	92-100	heterogeneous nuclear ribonucleoprotein A1	Mus musculus	131-139
31948038-5	2020	Riluzole also demonstrated synergistic anti-glioblastoma (GBM) affects with mTOR inhibitors in vitro and in GBM xenografts in mice.	Riluzole	0-8	mechanistic target of rapamycin kinase	Mus musculus	76-80
31550457-6	2020	We found that INaP blockers, phenytoin (40 muM and 100 muM) and riluzole (10 muM), reduced gamma oscillations induced by optogenetic stimulation of CaMKII-expressing cells in CA1 networks.	Riluzole	64-72	NFKB inhibitor zeta	Homo sapiens	14-18
31469828-4	2019	We simulate the blockade of a persistent sodium current (INaP), proposed to underlie rhythm generation in pre-Botzinger complex (pre-BotC) respiratory neurons, via two distinct pharmacological mechanisms: (1) pore obstruction mediated by tetrodotoxin and (2) altered inactivation dynamics mediated by riluzole.	Riluzole	301-309	NFKB inhibitor zeta	Homo sapiens	57-61
31352711-6	2019	The same experiments were repeated using SH-SY5Y cells carrying the familial ALS-related G93A-SOD1 mutation and constitutively expressing two-fold increased whole-cell ROS levels with respect to wild-type cells: riluzole was ineffective in this paradigm.	Riluzole	212-220	superoxide dismutase 1	Homo sapiens	94-98
30896584-16	2019	The activity of ALP in both cell types is upregulated by high-dose riluzole, which may indicate that high-dose riluzole can increase osteogenic metabolism and subsequently accelerate bone healing process.	Riluzole	67-75	alkaline phosphatase, placental	Homo sapiens	16-19
31456913-5	2019	RESULTS: The channel agonist riluzole activated TRAAK and delayed the apoptosis of photoreceptor cells in ONL layer of rd1 mice.	Riluzole	29-37	potassium channel, subfamily K, member 4	Mus musculus	48-53
31456913-5	2019	RESULTS: The channel agonist riluzole activated TRAAK and delayed the apoptosis of photoreceptor cells in ONL layer of rd1 mice.	Riluzole	29-37	phosphodiesterase 6B, cGMP, rod receptor, beta polypeptide	Mus musculus	119-122
31456913-6	2019	Both at mRNA and protein levels, after riluzole treatment, TRAAK expression was significantly upregulated, when compared with the control and blank group.	Riluzole	39-47	potassium channel, subfamily K, member 4	Mus musculus	59-64
31456913-9	2019	CONCLUSION: Riluzole elevates the expression of TRAAK and inhibits the development of apoptosis.	Riluzole	12-20	potassium channel, subfamily K, member 4	Mus musculus	48-53
30896584-11	2019	ALP activity was slightly increased in hMSCs after treatment for 2 weeks with riluzole 150 ng/mL and slightly upregulated by 150% (150 ng/mL) and 90% (450 ng/mL) in hMSCs at 3 weeks.	Riluzole	78-86	alkaline phosphatase, placental	Homo sapiens	0-3
30896584-12	2019	In hOBs, ALP activity almost doubled after 2 weeks of culture with riluzole 150 ng/mL (P < 0.05).	Riluzole	67-75	alkaline phosphatase, placental	Homo sapiens	9-12
30896584-16	2019	The activity of ALP in both cell types is upregulated by high-dose riluzole, which may indicate that high-dose riluzole can increase osteogenic metabolism and subsequently accelerate bone healing process.	Riluzole	111-119	alkaline phosphatase, placental	Homo sapiens	16-19
30896584-17	2019	However, at high concentrations, riluzole leads to a decrease in osteogenic gene expression, including Runx2 and type 1 collagen.	Riluzole	33-41	RUNX family transcription factor 2	Homo sapiens	103-108
30978452-4	2019	We demonstrated that riluzole significantly inhibited HU210-induced glutamate release through increased expression of glial glutamate transporter-1 (GLT-1) in cultured astrocytes, and an infusion of riluzole into the bilateral VTA in rats prevented the potent cannabinoid HU210-facilitated LTD induction in 2-month-old animals, which was blocked by bath application of dihydrokainate (DHK), a selective GLT-1 inhibitor.	Riluzole	199-207	solute carrier family 1 member 2	Rattus norvegicus	118-154
31300701-5	2019	We found that 12 compounds, including riluzole, which is an approved medication for ALS patients, ameliorated the phenotype of the dnc-1 KD animals.	Riluzole	38-46	Dynactin domain-containing protein;Dynactin subunit 1	Caenorhabditis elegans	131-136
30484112-0	2019	Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model.	Riluzole	0-8	cAMP responsive element binding protein 1	Rattus norvegicus	85-90
30484112-5	2019	Subsequently, analysis of the transcriptomics data revealed that Riluzole is predicted to reduce the activity of CREB1, a transcription factor that regulates the expression of multiple proteins that interact in a molecular landscape involved in apoptosis.	Riluzole	65-73	cAMP responsive element binding protein 1	Rattus norvegicus	113-118
30484112-6	2019	Although this mechanism underlying the beneficial effect of Riluzole on AIMs needs to be confirmed, it provides clues towards novel or existing compounds for the treatment of AIMs that modulate the activity of CREB1 and, hence, its downstream targets.	Riluzole	60-68	cAMP responsive element binding protein 1	Rattus norvegicus	210-215
30978452-4	2019	We demonstrated that riluzole significantly inhibited HU210-induced glutamate release through increased expression of glial glutamate transporter-1 (GLT-1) in cultured astrocytes, and an infusion of riluzole into the bilateral VTA in rats prevented the potent cannabinoid HU210-facilitated LTD induction in 2-month-old animals, which was blocked by bath application of dihydrokainate (DHK), a selective GLT-1 inhibitor.	Riluzole	21-29	solute carrier family 1 member 2	Rattus norvegicus	118-154
30153634-0	2018	Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression.	Riluzole	100-108	brain derived neurotrophic factor	Homo sapiens	17-50
30978452-4	2019	We demonstrated that riluzole significantly inhibited HU210-induced glutamate release through increased expression of glial glutamate transporter-1 (GLT-1) in cultured astrocytes, and an infusion of riluzole into the bilateral VTA in rats prevented the potent cannabinoid HU210-facilitated LTD induction in 2-month-old animals, which was blocked by bath application of dihydrokainate (DHK), a selective GLT-1 inhibitor.	Riluzole	21-29	solute carrier family 1 member 2	Rattus norvegicus	149-154
30974102-1	2019	In amyotrophic lateral sclerosis (ALS), upregulation in expression and activity of the ABC transporter P-glycoprotein (P-gp) driven by disease advancement progressively reduces CNS penetration and efficacy of the ALS drug, riluzole.	Riluzole	223-231	ATP binding cassette subfamily B member 1	Homo sapiens	119-123
31118868-4	2019	Pharmacological approved treatments for ALS are still limited and include riluzole and edaravone which improve survival over time.	Riluzole	74-82	superoxide dismutase 1	Homo sapiens	40-43
30280407-0	2019	Riluzole induces AR degradation via endoplasmic reticulum stress pathway in androgen-dependent and castration-resistant prostate cancer cells.	Riluzole	0-8	androgen receptor	Homo sapiens	17-19
30280407-11	2019	RESULTS: We demonstrate that riluzole downregulates AR-FL, mutant ARs, and AR-V7 proteins expression by protein degradation through ERS pathway and selective autophagy.	Riluzole	29-37	androgen receptor	Homo sapiens	52-57
30280407-12	2019	Riluzole also significantly inhibited AR transcription activity by decreasing its target genes expression (PSA, TMPRSS2, and KLK2).	Riluzole	0-8	androgen receptor	Homo sapiens	38-40
30280407-12	2019	Riluzole also significantly inhibited AR transcription activity by decreasing its target genes expression (PSA, TMPRSS2, and KLK2).	Riluzole	0-8	transmembrane serine protease 2	Homo sapiens	112-119
30280407-12	2019	Riluzole also significantly inhibited AR transcription activity by decreasing its target genes expression (PSA, TMPRSS2, and KLK2).	Riluzole	0-8	kallikrein related peptidase 2	Homo sapiens	125-129
30280407-13	2019	CONCLUSIONS: We provide key mechanistic insights by which riluzole exerts its anti-tumorigenic effects and induces AR protein degradation via ERS pathways.	Riluzole	58-66	androgen receptor	Homo sapiens	115-117
30413532-6	2019	Importantly, treatment with riluzole, which can activate TRPC5 in endothelial cells, improved recovery from ischemia in mice.	Riluzole	28-36	transient receptor potential cation channel, subfamily C, member 5	Mus musculus	57-62
30413532-7	2019	Our study reveals TRPC5 as a potential angiogenic target and suggests riluzole as a promising drug for managing ischemic diseases.	Riluzole	70-78	transient receptor potential cation channel, subfamily C, member 5	Mus musculus	18-23
30153634-2	2018	Pre-clinical and clinical reports suggest that the glutamate release inhibitor riluzole increases BDNF and may have antidepressant properties.	Riluzole	79-87	brain derived neurotrophic factor	Homo sapiens	98-102
30153634-5	2018	RESULTS: Riluzole responders had lower baseline serum (19.08 ng/ml [SD 9.22] v. 28.80 ng/ml [9.63], p = 0.08) and plasma (2.72 ng/ml [1.07] v. 4.60 ng/ml [1.69], p = 0.06) BDNF compared to non-responders at a trend level.	Riluzole	9-17	brain derived neurotrophic factor	Homo sapiens	172-176
30153634-8	2018	CONCLUSIONS: Preliminary evidence reported here suggests that lower baseline BDNF may be associated with better clinical response to riluzole.	Riluzole	133-141	brain derived neurotrophic factor	Homo sapiens	77-81
29704642-0	2018	Verapamil and riluzole cocktail liposomes overcome pharmacoresistance by inhibiting P-glycoprotein in brain endothelial and astrocyte cells: A potent approach to treat amyotrophic lateral sclerosis.	Riluzole	14-22	phosphoglycolate phosphatase	Mus musculus	84-98
30409714-5	2018	Moreover, riluzole prevented cold allodynia and increase in levels of TRPM8 mRNA in oxaliplatin-treated rats.	Riluzole	10-18	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	70-75
30409714-6	2018	These results suggest that riluzole prevents oxaliplatin-induced cold allodynia via inhibition of TRPM8 overexpression in the DRG.	Riluzole	27-35	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	98-103
30464577-0	2018	Riluzole induces LTD of spinal nociceptive signaling via postsynaptic GluR2 receptors.	Riluzole	0-8	glutamate ionotropic receptor AMPA type subunit 2	Homo sapiens	70-75
30464577-10	2018	Finally, endocytosis of post-synaptic GluR2 contributes to the riluzole-induced long-term depression (LTD) of the spinal nociceptive pathway.	Riluzole	63-71	glutamate ionotropic receptor AMPA type subunit 2	Homo sapiens	38-43
30464577-11	2018	Conclusion: The present study finds that riluzole induces LTD of nociceptive signaling in the SDH and produces long-lasting anti-allodynia effects in nerve injury-induced neuropathic pain conditions via postsynaptic AMPA receptors associated with the endocytosis of GluR2.	Riluzole	41-49	glutamate ionotropic receptor AMPA type subunit 2	Homo sapiens	266-271
29934198-1	2018	BACKGROUND: Rasagiline, a monoamine oxidase B inhibitor with neuroprotective potential in Parkinson"s disease, has shown a disease-modifying effect in the SOD1-Gly93Ala low-expressing mouse model of amyotrophic lateral sclerosis, both alone and in combination with riluzole.	Riluzole	265-273	superoxide dismutase 1, soluble	Mus musculus	155-159
29908238-5	2018	We tested the hypothesis that riluzole inhibits neuropathic pain behaviors by inhibiting pain-related changes in CeA neurons, in part at least through SK channel activation.	Riluzole	30-38	carcinoembryonic antigen gene family 4	Rattus norvegicus	113-116
29908238-10	2018	SNL rats had increased vocalizations and decreased withdrawal thresholds compared to sham rats, and intra-CeA administration of riluzole inhibited vocalizations and depression-like behaviors but did not affect withdrawal thresholds.	Riluzole	128-136	carcinoembryonic antigen gene family 4	Rattus norvegicus	106-109
29908238-12	2018	SK channel blockade in the CeA attenuated the inhibitory effects of systemic riluzole on vocalizations, confirming SK channel involvement in these effects.	Riluzole	77-85	carcinoembryonic antigen gene family 4	Rattus norvegicus	27-30
30425240-3	2018	Microarray analyses on two human melanoma cell lines revealed that riluzole stimulates expression of the cystine-glutamate amino acid antiporter, xCT (SLC7A11).	Riluzole	67-75	solute carrier family 7 member 11	Homo sapiens	146-149
30425240-3	2018	Microarray analyses on two human melanoma cell lines revealed that riluzole stimulates expression of the cystine-glutamate amino acid antiporter, xCT (SLC7A11).	Riluzole	67-75	solute carrier family 7 member 11	Homo sapiens	151-158
30425240-7	2018	The elevated xCT expression promoted cell proliferation in vitro and inversely, these melanoma clones showed a dose-dependent decrease in cell proliferation in response to riluzole treatment.	Riluzole	172-180	solute carrier family 7 member 11	Homo sapiens	13-16
30425240-9	2018	Conversely, treatment of xenograft-bearing animals with riluzole down-regulated xCT expression suggesting that xCT is a molecular target of riluzole.	Riluzole	56-64	solute carrier family 7 member 11	Homo sapiens	80-83
30425240-9	2018	Conversely, treatment of xenograft-bearing animals with riluzole down-regulated xCT expression suggesting that xCT is a molecular target of riluzole.	Riluzole	56-64	solute carrier family 7 member 11	Homo sapiens	111-114
30425240-9	2018	Conversely, treatment of xenograft-bearing animals with riluzole down-regulated xCT expression suggesting that xCT is a molecular target of riluzole.	Riluzole	140-148	solute carrier family 7 member 11	Homo sapiens	80-83
30425240-9	2018	Conversely, treatment of xenograft-bearing animals with riluzole down-regulated xCT expression suggesting that xCT is a molecular target of riluzole.	Riluzole	140-148	solute carrier family 7 member 11	Homo sapiens	111-114
30425240-10	2018	Furthermore, protein lysates from tumor biopsies of patients that participated in a riluzole monotherapy phase II clinical trial showed a reduction in xCT levels in post-treatment specimens from patients with stable disease.	Riluzole	84-92	solute carrier family 7 member 11	Homo sapiens	151-154
30425240-11	2018	Taken together, our results show that xCT may be utilized as a marker to monitor patients undergoing riluzole-based chemotherapies.	Riluzole	101-109	solute carrier family 7 member 11	Homo sapiens	38-41
30409714-0	2018	Riluzole prevents oxaliplatin-induced cold allodynia via inhibition of overexpression of transient receptor potential melastatin 8 in rats.	Riluzole	0-8	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	89-130
30409714-4	2018	In cultured DRG neurons, riluzole suppressed oxalate-induced increase of the number of menthol (TRPM8 agonist)-sensitive cells.	Riluzole	25-33	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	96-101
30056126-0	2018	Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin.	Riluzole	43-51	potassium two pore domain channel subfamily K member 2	Homo sapiens	14-20
30056126-5	2018	All the beneficial effects are due to riluzole action on the TREK-1 potassium channel, which plays a central role in its therapeutic action.	Riluzole	38-46	potassium two pore domain channel subfamily K member 2	Homo sapiens	61-67
30012693-9	2018	Finally, we found that 5 mum riluzole, which is known to block INaP, altered SNA by reducing episode duration and increasing inter-episode interval.	Riluzole	29-37	NFKB inhibitor zeta	Homo sapiens	63-67
30108205-3	2018	However, riluzole"s effect on amyloid beta (Abeta) pathology, a major histopathological hallmark of AD, remains unclear.	Riluzole	9-17	amyloid beta (A4) precursor protein	Mus musculus	44-49
30108205-5	2018	Riluzole significantly enhanced cognition and reduced Abeta42, Abeta40, Abeta oligomers levels, and Abeta plaque load in 5XFAD mice.	Riluzole	0-8	amyloid beta (A4) precursor protein	Mus musculus	54-59
30108205-5	2018	Riluzole significantly enhanced cognition and reduced Abeta42, Abeta40, Abeta oligomers levels, and Abeta plaque load in 5XFAD mice.	Riluzole	0-8	amyloid beta (A4) precursor protein	Mus musculus	63-68
30108205-8	2018	These data demonstrate that riluzole exerts a disease modifying effect in an Abeta mouse model of early-onset familial AD.	Riluzole	28-36	amyloid beta (A4) precursor protein	Mus musculus	77-82
29704642-2	2018	However, brain disposition of riluzole, as a substrate of P-glycoprotein (P-gp), is limited by the efflux transporters at the blood-brain barrier (BBB).	Riluzole	30-38	phosphoglycolate phosphatase	Mus musculus	58-72
29704642-2	2018	However, brain disposition of riluzole, as a substrate of P-glycoprotein (P-gp), is limited by the efflux transporters at the blood-brain barrier (BBB).	Riluzole	30-38	phosphoglycolate phosphatase	Mus musculus	74-78
29704642-3	2018	We propose to develop a liposomal co-delivery system that could effectively transport riluzole to brain cells by reducing efflux pumps with a P-gp inhibitor, verapamil.	Riluzole	86-94	phosphoglycolate phosphatase	Mus musculus	142-146
29731275-6	2018	Therapy with CDCA and Riluzole resulted in quantifiable improvement on the Scale for the Assessment and Rating of Ataxia (SARA).	Riluzole	22-30	secretion associated Ras related GTPase 1A	Homo sapiens	122-126
29357349-8	2018	The glutamate release inhibitor riluzole significantly suppressed premature death phenotypes induced by neuronal and glial knockdown of wfs1.	Riluzole	32-40	wolfram syndrome 1	Drosophila melanogaster	136-140
30034613-3	2018	Riluzole also strongly suppresses the growth of melanoma cells that express the type 1 metabotropic glutamate receptor (GRM1, mGluR1).	Riluzole	0-8	glutamate metabotropic receptor 1	Homo sapiens	120-124
30034613-3	2018	Riluzole also strongly suppresses the growth of melanoma cells that express the type 1 metabotropic glutamate receptor (GRM1, mGluR1).	Riluzole	0-8	glutamate metabotropic receptor 1	Homo sapiens	126-132
30034613-4	2018	Riluzole is a substrate for the variably expressed liver isozyme CYP1A2, which has been shown to contribute to the variance in exposure of riluzole in humans upon oral administration.	Riluzole	0-8	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	65-71
30034613-4	2018	Riluzole is a substrate for the variably expressed liver isozyme CYP1A2, which has been shown to contribute to the variance in exposure of riluzole in humans upon oral administration.	Riluzole	139-147	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	65-71
29341886-6	2018	Methylene blue (MB) and riluzole, two clinical available drugs, increase the amount of the monomeric HSF1 in both cells and animals.	Riluzole	24-32	heat shock transcription factor 1	Homo sapiens	101-105
29196977-7	2018	We demonstrated that SCA6-derived Purkinje cells exhibit vulnerability to triiodothyronine depletion, which is suppressed by treatment with thyrotropin-releasing hormone and Riluzole.	Riluzole	174-182	calcium voltage-gated channel subunit alpha1 A	Homo sapiens	21-25
29453787-0	2018	A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.	Riluzole	20-28	glutamate metabotropic receptor 1	Homo sapiens	47-80
29453787-0	2018	A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.	Riluzole	20-28	glutamate metabotropic receptor 1	Homo sapiens	82-86
29453787-2	2018	We performed a phase II trial of 100 mg PO bid of riluzole, an inhibitor of GRM1 signaling, in patients with advanced melanoma with the primary endpoint of response rate.	Riluzole	50-58	glutamate metabotropic receptor 1	Homo sapiens	76-80
28990593-0	2018	Riluzole Impairs Cocaine Reinstatement and Restores Adaptations in Intrinsic Excitability and GLT-1 Expression.	Riluzole	0-8	solute carrier family 1 member 2	Rattus norvegicus	94-99
28990593-7	2018	Riluzole also reversed the cocaine-induced suppression of the high-affinity glutamate transporter 1 (EAAT2/GLT-1) in the nucleus accumbens (NAc).	Riluzole	0-8	solute carrier family 1 member 2	Rattus norvegicus	101-106
28990593-7	2018	Riluzole also reversed the cocaine-induced suppression of the high-affinity glutamate transporter 1 (EAAT2/GLT-1) in the nucleus accumbens (NAc).	Riluzole	0-8	solute carrier family 1 member 2	Rattus norvegicus	107-112
29155254-14	2018	RESULTS: Animals treated with the association of riluzole and dantrolene showed a larger number of NeuN-positive neurons adjacent to the epicenter of injury (p&lt;=.05).	Riluzole	49-57	RNA binding fox-1 homolog 3	Rattus norvegicus	99-103
29396541-0	2018	TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole.	Riluzole	92-100	TAR DNA binding protein	Homo sapiens	0-6
29396541-5	2018	A screen of pharmacologically active compounds from the LOPAC 1280 library identified auranofin, chelerythrine and riluzole as dose-dependent inhibitors of TDP-43 self-interaction.	Riluzole	115-123	TAR DNA binding protein	Homo sapiens	156-162
29169345-2	2017	In this study, we examined the effects of riluzole, a sustained activator of the TRAAK potassium channel, on human RPE (ARPE-19) cells in an oxidant-induced cell-injury model and elucidate the mechanism of riluzole on RPE cell apoptosis.	Riluzole	42-50	potassium two pore domain channel subfamily K member 4	Homo sapiens	81-86
29161243-10	2018	In fact, similar results were produced by Riluzole, which is able to both activate KCa3.1 and inhibit Kv11.1.	Riluzole	42-50	potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4	Mus musculus	83-89
29161243-10	2018	In fact, similar results were produced by Riluzole, which is able to both activate KCa3.1 and inhibit Kv11.1.	Riluzole	42-50	potassium channel, subfamily V, member 2	Mus musculus	102-108
29161243-14	2018	CONCLUSIONS: As Riluzole, an activator of KCa3.1 and inhibitor of Kv11.1 channels, is in clinical use, our results suggest that this compound may be useful in the clinic to improve Cisplatin efficacy and overcome Cisplatin resistance in CRC.	Riluzole	16-24	potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4	Mus musculus	42-48
29161243-14	2018	CONCLUSIONS: As Riluzole, an activator of KCa3.1 and inhibitor of Kv11.1 channels, is in clinical use, our results suggest that this compound may be useful in the clinic to improve Cisplatin efficacy and overcome Cisplatin resistance in CRC.	Riluzole	16-24	potassium channel, subfamily V, member 2	Mus musculus	66-72
29493465-4	2018	Riluzole noncompetitive metabotropic glutamate receptor 1 (mGluR1) antagonist, commonly used to treat patients with amyotrophic lateral sclerosis (ALS), has shown some antineoplastic properties against melanoma, breast and prostate cancer.	Riluzole	0-8	glutamate metabotropic receptor 1	Homo sapiens	24-57
29493465-4	2018	Riluzole noncompetitive metabotropic glutamate receptor 1 (mGluR1) antagonist, commonly used to treat patients with amyotrophic lateral sclerosis (ALS), has shown some antineoplastic properties against melanoma, breast and prostate cancer.	Riluzole	0-8	glutamate metabotropic receptor 1	Homo sapiens	59-65
29493465-9	2018	RESULT: At the molecular level, we found that these cells treated with Riluzole had a decrease of Cyclin B and an increase of p21 Waf1/Cip1 and p53 expression.	Riluzole	71-79	cyclin dependent kinase inhibitor 1A	Homo sapiens	126-139
29493465-9	2018	RESULT: At the molecular level, we found that these cells treated with Riluzole had a decrease of Cyclin B and an increase of p21 Waf1/Cip1 and p53 expression.	Riluzole	71-79	tumor protein p53	Homo sapiens	144-147
29169345-10	2017	The protection mechanism of riluzole could be from stabilizing mitochondrial Deltapsim and preventing the release of Cyt-c.	Riluzole	28-36	cytochrome c, somatic	Homo sapiens	117-122
28872909-5	2017	The current status of treatment for ALS includes one drug riluzole that slows progression modestly, and another drug edaravone that was recently approved by FDA to slow ALS progression.	Riluzole	58-66	superoxide dismutase 1	Homo sapiens	36-39
28779378-4	2017	Recent studies reported that overexpression of P-glycoprotein and increase in its activity at the BBB drives a progressive resistance to CNS penetration and persistence of riluzole, the only drug approved thus far for treatment of amyotrophic lateral sclerosis (ALS), rapidly progressive and mostly fatal neurologic disease.	Riluzole	172-180	ATP binding cassette subfamily B member 1	Homo sapiens	47-61
28851920-8	2017	The administration of riluzole, an approved drug for amyotrophic lateral sclerosis, suppressed the increase of glutamate concentration, the decrease of GLT-1 expression and the development of mechanical allodynia.	Riluzole	22-30	solute carrier family 1 member 2	Rattus norvegicus	152-157
28953220-2	2017	An ALS drug, Riluzole, has been shown to induce two different anticancer effects on hepatocellular carcinoma (HCC).	Riluzole	13-21	HCC	Homo sapiens	110-113
28813081-5	2017	Results: Riluzole increased the survival rates of patients with lower limb onset who were diagnosed after the first appointment in B19.	Riluzole	9-17	hormonally up-regulated Neu-associated kinase	Homo sapiens	131-134
27693446-5	2016	Also, PPB effectively suppressed the riluzole-sensitive, persistent sodium current (INaP).	Riluzole	37-45	NFKB inhibitor zeta	Homo sapiens	84-88
28525376-8	2017	Riluzole can lead to further decrease in NAD+ (nicotinamide adenine dinucleotide) and lactate dehydrogenase-A (LDHA) expressions which in turn further heightened oxidative stress in CR cells.	Riluzole	0-8	lactate dehydrogenase A	Homo sapiens	86-109
28525376-8	2017	Riluzole can lead to further decrease in NAD+ (nicotinamide adenine dinucleotide) and lactate dehydrogenase-A (LDHA) expressions which in turn further heightened oxidative stress in CR cells.	Riluzole	0-8	lactate dehydrogenase A	Homo sapiens	111-115
28525376-9	2017	LDHA knocked-down cells became hypersensitive to riluzole treatments and possessed increased levels of ROS.	Riluzole	49-57	lactate dehydrogenase A	Homo sapiens	0-4
28525376-14	2017	Riluzole may serve as a dual-targeting agent by suppression LDHA and blocking xCT antiporter.	Riluzole	0-8	lactate dehydrogenase A	Homo sapiens	60-64
28525376-14	2017	Riluzole may serve as a dual-targeting agent by suppression LDHA and blocking xCT antiporter.	Riluzole	0-8	solute carrier family 7 member 11	Homo sapiens	78-81
26896755-6	2017	Further, we discuss the evolution of riluzole, a glutamate release inhibitor approved for amyotrophic lateral sclerosis (ALS), but now fashioned as an mGluR1 inhibitor for melanoma therapy and as a radio-sensitizer for tumors that have metastasized to the brain.	Riluzole	37-45	glutamate metabotropic receptor 1	Homo sapiens	151-157
26896755-7	2017	With the success of riluzole, it is not far-fetched to believe that other drugs that may act directly or indirectly on other mGluRs can be beneficial for multiple applications.	Riluzole	20-28	glutamyl-tRNA synthetase 2, mitochondrial	Mus musculus	125-131
27021815-6	2017	Riluzole is known to increase the glutamate transporter EAAT2"s ability to scavenge excess glutamate, regulating synaptic transmission.	Riluzole	0-8	solute carrier family 1 member 2	Rattus norvegicus	56-61
27021815-7	2017	RNA-seq and immunohistochemistry confirmed an increase in EAAT2 expression in hippocampus, identifying a possible mechanism underlying the improved memory function after riluzole treatment.	Riluzole	170-178	solute carrier family 1 member 2	Rattus norvegicus	58-63
27939241-8	2017	Furthermore, the increased expression of MCP1 in AGE- or mLDL-treated cultured retinal pericytes was inhibited by treatment with riluzole or the PKC inhibitor GF109203X.	Riluzole	129-137	chemokine (C-C motif) ligand 2	Mus musculus	41-45
27939241-10	2017	Taken together, our results demonstrate that riluzole attenuates both MCP1 induction and pericyte loss in diabetic retinopathy, likely through its direct inhibitory effect on PKC.	Riluzole	45-53	chemokine (C-C motif) ligand 2	Mus musculus	70-74
28591718-7	2017	While both drugs inhibited breast cancer cell proliferation, there were distinct functional effects suggesting that riluzole action may be metabotropic glutamate receptor 1-independent.	Riluzole	116-124	glutamate metabotropic receptor 1	Homo sapiens	139-172
29228563-6	2017	The effects of riluzole on these cells were associated with an inhibition of a poor prognostic indicator: glucose transporter 3 (GLUT3).	Riluzole	15-23	solute carrier family 2 member 3	Homo sapiens	106-127
29228563-6	2017	The effects of riluzole on these cells were associated with an inhibition of a poor prognostic indicator: glucose transporter 3 (GLUT3).	Riluzole	15-23	solute carrier family 2 member 3	Homo sapiens	129-134
28462043-4	2017	The aim of this study was to evaluate the effects of chronic riluzole treatment on a novel HD-like transgenic mouse model, based on the genetic ablation of the transcription factor TIF-IA.	Riluzole	61-69	Jun dimerization protein 2	Mus musculus	181-184
28049095-6	2017	Further biochemical analysis showed that riluzole pretreatment of intrahippocampal Abeta-microinjected rats is able to attenuate hippocampal AChE activity and lower some oxidative stress markers, i.e. MDA and nitrite, with no significant change of the defensive enzyme catalase.	Riluzole	41-49	acetylcholinesterase	Rattus norvegicus	141-145
28049095-8	2017	It is concluded that riluzole could exert a protective effect against memory decline induced by intrahippocampal Abeta25-35 through anti-oxidative, anti-cholinesterase, and neuroprotective potential and its beneficial effect is possibly independent of cholinoceptor activation.	Riluzole	21-29	butyrylcholinesterase	Rattus norvegicus	153-167
28193882-9	2017	The EAD-like waveforms of Scn8aN1768D/+ CA1 hippocampal neurons were blocked by tetrodotoxin, riluzole, and SN-6, implicating elevated persistent INa and reverse mode Na/Ca exchange in the mechanism of hyperexcitability.	Riluzole	94-102	carbonic anhydrase 1	Mus musculus	40-43
28231291-7	2017	We also show that Riluzole alters the phosphorylation status of AKT/P70 S6 kinase, ERK1/2 and JNK1/2.	Riluzole	18-26	AKT serine/threonine kinase 1	Homo sapiens	64-67
28231291-7	2017	We also show that Riluzole alters the phosphorylation status of AKT/P70 S6 kinase, ERK1/2 and JNK1/2.	Riluzole	18-26	mitogen-activated protein kinase 3	Homo sapiens	83-89
28231291-7	2017	We also show that Riluzole alters the phosphorylation status of AKT/P70 S6 kinase, ERK1/2 and JNK1/2.	Riluzole	18-26	mitogen-activated protein kinase 8	Homo sapiens	94-100
28060747-4	2017	In the motor neuron-like cell line (NSC34) with the human mutant G93A superoxide dismutase 1 gene (mSOD1-G93A), 25-hydroxycholesterol induced motor neuronal death/ apoptosis via glycogen synthase kinase-3beta and liver X receptor pathways; riluzole treatment attenuated these effects.	Riluzole	240-248	superoxide dismutase 1	Homo sapiens	70-92
28060747-4	2017	In the motor neuron-like cell line (NSC34) with the human mutant G93A superoxide dismutase 1 gene (mSOD1-G93A), 25-hydroxycholesterol induced motor neuronal death/ apoptosis via glycogen synthase kinase-3beta and liver X receptor pathways; riluzole treatment attenuated these effects.	Riluzole	240-248	superoxide dismutase 1, soluble	Mus musculus	99-104
28111541-0	2016	Riluzole But Not Melatonin Ameliorates Acute Motor Neuron Degeneration and Moderately Inhibits SOD1-Mediated Excitotoxicity Induced Disrupted Mitochondrial Ca2+ Signaling in Amyotrophic Lateral Sclerosis.	Riluzole	0-8	CLN8 transmembrane ER and ERGIC protein	Mus musculus	45-70
27612558-5	2016	In addition, Riluzole induced caspase-dependent apoptosis and G2/M cell cycle arrest in SNU449 and Huh7 cell lines.	Riluzole	13-21	MIR7-3 host gene	Homo sapiens	99-103
27612558-7	2016	We confirm this finding in vivo by showing the Riluzole-induced GSH and ROS changes in a Huh7 xenograft cancer model.	Riluzole	47-55	MIR7-3 host gene	Homo sapiens	89-93
27146584-3	2016	However, the role of GRM1 in mediating riluzole"s effects in breast cancer has not been fully elucidated.	Riluzole	39-47	glutamate metabotropic receptor 1	Homo sapiens	21-25
27126806-7	2016	ITH33 and riluzole were neuroprotective against VTD, blocked the maximum peak and the number of [Ca(2+)]c oscillations per cell, and restored the effect on parvalbumin.	Riluzole	10-18	parvalbumin	Homo sapiens	156-167
27806289-6	2016	We further demonstrate that SCA6 Purkinje cells exhibit thyroid hormone depletion-dependent degeneration, which can be suppressed by two compounds, thyroid releasing hormone and Riluzole.	Riluzole	178-186	calcium voltage-gated channel subunit alpha1 A	Homo sapiens	28-32
27287370-5	2016	Two compounds (37, 39) were identified as potent ABAD inhibitors, where compound 39 exhibited comparable cytotoxicity with the frentizole standard; however, one-fold higher cytotoxicity than the parent riluzole standard.	Riluzole	202-210	hydroxysteroid 17-beta dehydrogenase 10	Homo sapiens	49-53
26990650-0	2016	In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.	Riluzole	22-30	ataxin 3	Mus musculus	67-96
26990650-8	2016	Post-symptomatic treatment with riluzole carried out for a period of 10 months led to reduction of the soluble ataxin-3 level and an increase in ataxin-3 positive accumulations, but did not improve motor deficits measured by rotarod.	Riluzole	32-40	ataxin 3	Mus musculus	111-119
26990650-8	2016	Post-symptomatic treatment with riluzole carried out for a period of 10 months led to reduction of the soluble ataxin-3 level and an increase in ataxin-3 positive accumulations, but did not improve motor deficits measured by rotarod.	Riluzole	32-40	ataxin 3	Mus musculus	145-153
26990650-10	2016	We even observed a pronounced reduction of calbindin expression in Purkinje cells in riluzole-treated mice.	Riluzole	85-93	calbindin 1	Mus musculus	43-52
26990650-12	2016	Assessing riluzole as a potential treatment for spinocerebellar ataxia type 3 (SCA3) had no beneficial, but rather a worsening effect on our transgenic SCA3 mouse model.	Riluzole	10-18	ataxin 3	Mus musculus	48-77
26990650-13	2016	We hypothesize that: Riluzole treatment enhanced glutamate release in ATXN3-expressing cells leading to an increased Ca(2+) influx resulting in Purkinje cell damage shown by loss of calbindin expression.	Riluzole	21-29	ataxin 3	Mus musculus	70-75
26990650-13	2016	We hypothesize that: Riluzole treatment enhanced glutamate release in ATXN3-expressing cells leading to an increased Ca(2+) influx resulting in Purkinje cell damage shown by loss of calbindin expression.	Riluzole	21-29	calbindin 1	Mus musculus	182-191
27146584-4	2016	In this study, we seek to determine how much of riluzole"s action in breast cancer is mediated through GRM1.	Riluzole	48-56	glutamate metabotropic receptor 1	Homo sapiens	103-107
27146584-8	2016	There was a trend between GRM1 expression in TNBC cells and their response to riluzole in both cell proliferation and invasion assays.	Riluzole	78-86	glutamate metabotropic receptor 1	Homo sapiens	26-30
27146584-10	2016	Our results clearly suggest a GRM1-independent mechanism through which riluzole mediates its effects on breast cancer cells.	Riluzole	71-79	glutamate metabotropic receptor 1	Homo sapiens	30-34
26099215-6	2016	OBJECTIVES: The primary objective of the trial is to evaluate the superiority of riluzole, at a dose of 100 mg BID in the first 24 h followed by 50 mg BID for the following 13 days post injury, compared with placebo in improving neurological motor outcomes in patients with C4-C8 level, International Standards for Neurological Classification of Spinal Cord Injury Examination (ISNCSCI) grade A, B or C acute (within 12 h post injury) SCI.	Riluzole	81-89	BH3 interacting domain death agonist	Homo sapiens	111-114
26269549-4	2015	The Po of KNa channels was also found to be reduced by bath application of a high concentration of TTX (1 muM) and riluzole (100 muM), which inhibits both fast (INaf) and persistent (INaP) Na(+) currents, whereas it was unaffected by a low concentration of TTX (10 nM), which selectively blocks INaf.	Riluzole	115-123	latexin	Homo sapiens	129-132
26146790-6	2015	Riluzole also attenuated the TauP301L-mediated increase in hippocampal vesicular glutamate transporter 1, which packages glutamate into vesicles and influences glutamate release; and the TauP301L-mediated decrease in hippocampal glutamate transporter 1, the major transporter responsible for removing glutamate from the extracellular space.	Riluzole	0-8	solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7	Mus musculus	71-104
26146790-7	2015	The TauP301L-mediated reduction in PSD-95 expression, a marker of excitatory synapses in the hippocampus, was also rescued by riluzole.	Riluzole	126-134	discs large MAGUK scaffold protein 4	Mus musculus	35-41
26269549-4	2015	The Po of KNa channels was also found to be reduced by bath application of a high concentration of TTX (1 muM) and riluzole (100 muM), which inhibits both fast (INaf) and persistent (INaP) Na(+) currents, whereas it was unaffected by a low concentration of TTX (10 nM), which selectively blocks INaf.	Riluzole	115-123	NFKB inhibitor zeta	Homo sapiens	183-187
26321318-11	2015	The proportion with decreased SARA score was 14 (50%) of 28 patients in the riluzole group versus three (11%) of 27 in the placebo group (OR 8 00, 95% CI 1 95-32 83; p=0 002).	Riluzole	76-84	zinc finger FYVE-type containing 9	Homo sapiens	30-34
25734516-8	2015	The transient calcium current collaborates with INaP to generate burst firing, and selective blockade of INaP by riluzole significantly attenuated rebound burst firing and spontaneous activity.	Riluzole	113-121	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, zeta	Mus musculus	105-109
26071088-6	2015	While acute riluzole incubation induced CT-1 secretion by astrocytes and Schwann cells, chronic treatment stimulated a significant decrease in trophic factor production compared to untreated cultures.	Riluzole	12-20	cardiotrophin 1	Homo sapiens	40-44
26071088-11	2015	There was an increase in the production of CT-1 and GDNF in the spinal cord and CT-1 in the sciatic nerve during the first days of treatment with riluzole, but the levels dropped significantly after chronic treatment with the drug.	Riluzole	146-154	cardiotrophin 1	Homo sapiens	43-47
26071088-11	2015	There was an increase in the production of CT-1 and GDNF in the spinal cord and CT-1 in the sciatic nerve during the first days of treatment with riluzole, but the levels dropped significantly after chronic treatment with the drug.	Riluzole	146-154	glial cell derived neurotrophic factor	Homo sapiens	52-56
26071088-11	2015	There was an increase in the production of CT-1 and GDNF in the spinal cord and CT-1 in the sciatic nerve during the first days of treatment with riluzole, but the levels dropped significantly after chronic treatment with the drug.	Riluzole	146-154	cardiotrophin 1	Homo sapiens	80-84
26106294-6	2015	We further find that co-application of ACM-SOD1(G93A) with blockers of Nav channels (spermidine, mexiletine, or riluzole) or anti-oxidants (Trolox, esculetin, or tiron) effectively prevent c-Abl activation and motoneuron death.	Riluzole	112-120	superoxide dismutase 1	Homo sapiens	43-47
25538156-8	2015	Disruption of the crosstalk between nNav and RyR2 by nNav blockade with riluzole reduced and also desynchronized DCR in isolated cardiomyocytes and in intact cardiac tissue.	Riluzole	72-80	ryanodine receptor 2, cardiac	Mus musculus	45-49
25899939-3	2015	Here, we report the presence of a riluzole-activated current (IRIL ) that flows through the TREK-2 channels, and that is also inhibited by muscarinic agonists in neurons of the mouse superior cervical ganglion (mSCG).	Riluzole	34-42	potassium channel, subfamily K, member 10	Mus musculus	92-98
25858436-5	2015	Riluzole, an agent currently approved for the treatment of amyotrophic lateral sclerosis, is a glutamatergic modulator and BDNF enhancer with neuroprotective properties.	Riluzole	0-8	brain derived neurotrophic factor	Mus musculus	123-127
25749171-1	2015	Our group has previously reported that the majority of human melanomas (&gt;60%) express the metabotropic glutamate receptor 1 (GRM1) and that the glutamate release inhibitor riluzole, a drug currently used to treat amyotrophic lateral sclerosis, can induce apoptosis in GRM1-expressing melanoma cells.	Riluzole	175-183	glutamate metabotropic receptor 1	Homo sapiens	128-132
25472656-0	2015	Riluzole prevents soluble Abeta1-42 oligomers-induced perturbation of spontaneous discharge in the hippocampal CA1 region of rats.	Riluzole	0-8	carbonic anhydrase 1	Rattus norvegicus	111-114
25749171-1	2015	Our group has previously reported that the majority of human melanomas (&gt;60%) express the metabotropic glutamate receptor 1 (GRM1) and that the glutamate release inhibitor riluzole, a drug currently used to treat amyotrophic lateral sclerosis, can induce apoptosis in GRM1-expressing melanoma cells.	Riluzole	175-183	glutamate metabotropic receptor 1	Homo sapiens	271-275
25749171-2	2015	Our group previously reported that in vitro riluzole treatment reduces cell growth in three-dimensional (3D) soft agar colony assays by 80% in cells with wildtype phosphoinositide 3-kinase (PI3K) pathway activation.	Riluzole	44-52	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	163-188
25749171-3	2015	However, melanoma cell lines harboring constitutive activating mutations of the PI3K pathway (PTEN and NRAS mutations) showed only a 35% to 40% decrease in colony formation in soft agar in the presence of riluzole.	Riluzole	205-213	NRAS proto-oncogene, GTPase	Homo sapiens	103-107
25556802-11	2015	This in vitro preparation also revealed that riluzole, a blocker of the persistent sodium current (INap), abolished the modulatory effect on sighs, while flufenamic acid, an antagonist for the calcium-activated non-selective cation conductance (ICAN ) abolished the effect of PGE2 on fictive eupnoea at higher concentrations.	Riluzole	45-53	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, zeta	Mus musculus	99-103
25629040-7	2015	When platelets were incubated with riluzole for 4 h, the basal value of BDNF (92.9 +- 11.1 pg 10(-6) platelets) was significantly increased (P &lt; 0.05, n = 27).	Riluzole	35-43	brain derived neurotrophic factor	Homo sapiens	72-76
25629040-8	2015	This stimulatory effect was achieved at low concentrations of riluzole (from 10 microM) and was not observed when platelets were incubated with the drug for 24 h. The direct action of riluzole evoking BDNF release from human platelets at therapeutic concentrations is important and may contribute to the understanding of its mechanisms of action in the treatment of depression.	Riluzole	184-192	brain derived neurotrophic factor	Homo sapiens	201-205
25629040-0	2015	Riluzole stimulates BDNF release from human platelets.	Riluzole	0-8	brain derived neurotrophic factor	Homo sapiens	20-24
25629040-5	2015	Recently, riluzole has been proposed for the treatment of depression because it has the ability to lower extracellular glutamate levels and increase BDNF expression; and both mechanisms could be associated with its antidepressant action.	Riluzole	10-18	brain derived neurotrophic factor	Homo sapiens	149-153
25629040-6	2015	Considering that riluzole enhances BDNF levels in the serum of patients, we investigated if treatment with this drug could stimulate the release of this neurotrophin from human platelets obtained from healthy subjects.	Riluzole	17-25	brain derived neurotrophic factor	Homo sapiens	35-39
26399668-6	2015	At 16 months later, she wanted to take riluzole again.	Riluzole	39-47	Src homology 2 domain containing E	Homo sapiens	20-23
25363352-0	2015	Riluzole is a radio-sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells.	Riluzole	0-8	glutamate metabotropic receptor 1	Homo sapiens	91-95
25363352-4	2015	Here, we used orthotopic implanted GRM1 expressing human melanoma cell xenografts in mice, to demonstrate that animals receiving concurrent glutamate signaling blockade (riluzole) and radiation led to a decrease in intracranial tumor growth compared to either modality alone.	Riluzole	170-178	glutamate metabotropic receptor 1	Homo sapiens	35-39
25720096-8	2015	Riluzole is the only drug approved by the Food and Drug Administration and recommended by the National Institute for Clinical Excellence so far proven to be successful against ALS and may prevent progression and extend life for a few months or so.	Riluzole	0-8	superoxide dismutase 1	Homo sapiens	176-179
26399668-8	2015	Drug (riluzole)-induced lymphocyte stimulation tests (DLST) were negative two times.	Riluzole	6-14	dihydrolipoamide S-succinyltransferase	Homo sapiens	54-58
24078718-7	2014	There was no difference in anti-NF plasma antibodies between ALS individuals treated with riluzole and untreated patients; although riluzole-treated ALS cases with an earlier age of onset and with a shorter diagnostic delay displayed higher anti-NFL antibody levels compared to untreated ALS patients with similar features.	Riluzole	132-140	neurofilament light chain	Homo sapiens	246-249
26785244-8	2014	Combination treatment with Immunocal( ) and the anti-glutamatergic compound, riluzole, delayed disease onset and extended survival in hSOD1(G93A) mice.	Riluzole	77-85	superoxide dismutase 1	Homo sapiens	134-138
25574474-4	2014	METHODS: Here, we prove that a P-gp/BCRP-driven pharmacoresistance limits the bioavailability of ALS therapeutics using riluzole, the only FDA-approved drug for ALS and a substrate of P-gp and BCRP.	Riluzole	120-128	phosphoglycolate phosphatase	Mus musculus	31-35
25574474-4	2014	METHODS: Here, we prove that a P-gp/BCRP-driven pharmacoresistance limits the bioavailability of ALS therapeutics using riluzole, the only FDA-approved drug for ALS and a substrate of P-gp and BCRP.	Riluzole	120-128	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	36-40
25574474-4	2014	METHODS: Here, we prove that a P-gp/BCRP-driven pharmacoresistance limits the bioavailability of ALS therapeutics using riluzole, the only FDA-approved drug for ALS and a substrate of P-gp and BCRP.	Riluzole	120-128	phosphoglycolate phosphatase	Mus musculus	184-188
25574474-4	2014	METHODS: Here, we prove that a P-gp/BCRP-driven pharmacoresistance limits the bioavailability of ALS therapeutics using riluzole, the only FDA-approved drug for ALS and a substrate of P-gp and BCRP.	Riluzole	120-128	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	193-197
25574474-6	2014	RESULTS: We show that riluzole, which normally is not effective when given at onset of symptoms, is now effective in the ALS mice when administered in combination with the P-gp/BCRP inhibitor elacridar.	Riluzole	22-30	phosphoglycolate phosphatase	Mus musculus	172-176
25574474-6	2014	RESULTS: We show that riluzole, which normally is not effective when given at onset of symptoms, is now effective in the ALS mice when administered in combination with the P-gp/BCRP inhibitor elacridar.	Riluzole	22-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	177-181
25102326-8	2014	In the presence of riluzole (RLZ), an antagonist of INaP, the Abeta1-42-induced neuronal hyperexcitation and INaP augmentation were significantly inhibited.	Riluzole	19-27	NFKB inhibitor zeta	Homo sapiens	52-56
25102326-8	2014	In the presence of riluzole (RLZ), an antagonist of INaP, the Abeta1-42-induced neuronal hyperexcitation and INaP augmentation were significantly inhibited.	Riluzole	19-27	NFKB inhibitor zeta	Homo sapiens	109-113
25102326-8	2014	In the presence of riluzole (RLZ), an antagonist of INaP, the Abeta1-42-induced neuronal hyperexcitation and INaP augmentation were significantly inhibited.	Riluzole	29-32	NFKB inhibitor zeta	Homo sapiens	52-56
25102326-8	2014	In the presence of riluzole (RLZ), an antagonist of INaP, the Abeta1-42-induced neuronal hyperexcitation and INaP augmentation were significantly inhibited.	Riluzole	29-32	NFKB inhibitor zeta	Homo sapiens	109-113
23744878-0	2014	Riluzole: validation of stability-indicating HPLC, D1 and DD1 spectrophotometric assays.	Riluzole	0-8	aldo-keto reductase family 1 member C1	Homo sapiens	58-61
24678596-12	2014	At Day 7, axons labeled for NF200, CGRP, and IB4 in the compressed roots of animals that received riluzole treatment exhibited fewer axonal swellings than those from untreated animals.	Riluzole	98-106	calcitonin-related polypeptide alpha	Rattus norvegicus	35-39
24678596-13	2014	Riluzole also mitigated changes in the spinal distribution of CGRP and GLT-1 expression that is induced by a painful root compression, returning the spinal expression of both to sham levels.	Riluzole	0-8	calcitonin-related polypeptide alpha	Rattus norvegicus	62-66
24678596-13	2014	Riluzole also mitigated changes in the spinal distribution of CGRP and GLT-1 expression that is induced by a painful root compression, returning the spinal expression of both to sham levels.	Riluzole	0-8	solute carrier family 1 member 2	Rattus norvegicus	71-76
25512503-9	2014	Furthermore, riluzole-treated rats had an increase in clustering of thin spines that correlated with memory performance and was specific to the apical, but not the basilar, dendrites of CA1.	Riluzole	13-21	carbonic anhydrase 1	Rattus norvegicus	186-189
25490401-10	2014	Similarly the TASK 1/3 blocker zinc chloride (1 mM) gave a maximum relaxation of 72+-5% (n = 8; p&lt;0.01) which compared with the relaxation produced by the TREK-1 opener riluzole (75+-5%; n = 6).	Riluzole	172-180	potassium two pore domain channel subfamily K member 2	Homo sapiens	158-164
24491800-3	2014	Clinical evaluation of the GRM1 signaling inhibitor riluzole in patients with advanced melanoma has demonstrated tumor regressions that are associated with a suppression of the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathways.	Riluzole	52-60	glutamate metabotropic receptor 1	Homo sapiens	27-31
24491800-3	2014	Clinical evaluation of the GRM1 signaling inhibitor riluzole in patients with advanced melanoma has demonstrated tumor regressions that are associated with a suppression of the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathways.	Riluzole	52-60	protein tyrosine kinase 2 beta	Homo sapiens	247-263
24491800-3	2014	Clinical evaluation of the GRM1 signaling inhibitor riluzole in patients with advanced melanoma has demonstrated tumor regressions that are associated with a suppression of the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathways.	Riluzole	52-60	AKT serine/threonine kinase 1	Homo sapiens	270-273
24491800-7	2014	In clinical specimens from patients receiving riluzole, we confirmed an inhibition of MAPK and PI3K/AKT activation in posttreatment as compared with pretreatment tumor specimens, which exhibited a decreased density of blood vessels.	Riluzole	46-54	AKT serine/threonine kinase 1	Homo sapiens	100-103
24184328-8	2014	Riluzole also decreased the number of phosphorylated NR1 and phosphorylated NR2B positive cells in the dorsal horns and the microglia activation in the dorsal horns.	Riluzole	0-8	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	53-56
24330389-0	2014	Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells.	Riluzole	45-53	glutamate metabotropic receptor 1	Homo sapiens	14-18
24330389-4	2014	In this study, we investigate the mechanism of an inhibitor of glutamate release, riluzole, on human melanoma cells that express metabotropic glutamate receptor 1 (GRM1).	Riluzole	82-90	glutamate metabotropic receptor 1	Homo sapiens	129-162
24330389-4	2014	In this study, we investigate the mechanism of an inhibitor of glutamate release, riluzole, on human melanoma cells that express metabotropic glutamate receptor 1 (GRM1).	Riluzole	82-90	glutamate metabotropic receptor 1	Homo sapiens	164-168
24184328-8	2014	Riluzole also decreased the number of phosphorylated NR1 and phosphorylated NR2B positive cells in the dorsal horns and the microglia activation in the dorsal horns.	Riluzole	0-8	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	76-80
25548669-7	2014	In myotubes, riluzole (1 muM, a therapeutic concentration) reduced Na(+) current by 20%.	Riluzole	13-21	latexin	Homo sapiens	25-28
24117252-10	2014	Riluzole-induced TRPC5 currents were potentiated by La(3+) and, utilizing TRPC5 mutants that lack La(3+) binding sites, it was confirmed that riluzole and La(3+) activate TRPC5 by different mechanisms.	Riluzole	142-150	transient receptor potential cation channel subfamily C member 5	Homo sapiens	17-22
24117252-10	2014	Riluzole-induced TRPC5 currents were potentiated by La(3+) and, utilizing TRPC5 mutants that lack La(3+) binding sites, it was confirmed that riluzole and La(3+) activate TRPC5 by different mechanisms.	Riluzole	142-150	transient receptor potential cation channel subfamily C member 5	Homo sapiens	74-79
24117252-10	2014	Riluzole-induced TRPC5 currents were potentiated by La(3+) and, utilizing TRPC5 mutants that lack La(3+) binding sites, it was confirmed that riluzole and La(3+) activate TRPC5 by different mechanisms.	Riluzole	142-150	transient receptor potential cation channel subfamily C member 5	Homo sapiens	74-79
24117252-11	2014	Recordings of excised inside-out patches revealed a relatively direct effect of riluzole on TRPC5.	Riluzole	80-88	transient receptor potential cation channel subfamily C member 5	Homo sapiens	92-97
24117252-12	2014	CONCLUSIONS AND IMPLICATIONS: Riluzole can activate TRPC5 heterologously expressed in HEK293 cells as well as those endogenously expressed in the U-87 glioblastoma cell line.	Riluzole	30-38	transient receptor potential cation channel subfamily C member 5	Homo sapiens	52-57
24117252-13	2014	Riluzole does not activate any other member of the TRPC family and could, therefore, despite its action on other ion channels, be a useful pharmacological tool for identifying TRPC5-specific currents in immortalized cell lines or in acutely isolated primary cells.	Riluzole	0-8	transient receptor potential cation channel subfamily C member 5	Homo sapiens	176-181
24117252-0	2014	Riluzole activates TRPC5 channels independently of PLC activity.	Riluzole	0-8	transient receptor potential cation channel subfamily C member 5	Homo sapiens	19-24
24117252-9	2014	KEY RESULTS: Riluzole was identified as a novel activator of TRPC5 (EC50 9.2 +- 0.5 muM) and its mechanism of action was shown to be independent of G protein signalling and PLC activity.	Riluzole	13-21	transient receptor potential cation channel subfamily C member 5	Homo sapiens	61-66
24117252-9	2014	KEY RESULTS: Riluzole was identified as a novel activator of TRPC5 (EC50 9.2 +- 0.5 muM) and its mechanism of action was shown to be independent of G protein signalling and PLC activity.	Riluzole	13-21	latexin	Homo sapiens	84-87
24117252-9	2014	KEY RESULTS: Riluzole was identified as a novel activator of TRPC5 (EC50 9.2 +- 0.5 muM) and its mechanism of action was shown to be independent of G protein signalling and PLC activity.	Riluzole	13-21	heparan sulfate proteoglycan 2	Homo sapiens	173-176
24117252-10	2014	Riluzole-induced TRPC5 currents were potentiated by La(3+) and, utilizing TRPC5 mutants that lack La(3+) binding sites, it was confirmed that riluzole and La(3+) activate TRPC5 by different mechanisms.	Riluzole	0-8	transient receptor potential cation channel subfamily C member 5	Homo sapiens	17-22
24117252-10	2014	Riluzole-induced TRPC5 currents were potentiated by La(3+) and, utilizing TRPC5 mutants that lack La(3+) binding sites, it was confirmed that riluzole and La(3+) activate TRPC5 by different mechanisms.	Riluzole	0-8	transient receptor potential cation channel subfamily C member 5	Homo sapiens	74-79
24117252-10	2014	Riluzole-induced TRPC5 currents were potentiated by La(3+) and, utilizing TRPC5 mutants that lack La(3+) binding sites, it was confirmed that riluzole and La(3+) activate TRPC5 by different mechanisms.	Riluzole	0-8	transient receptor potential cation channel subfamily C member 5	Homo sapiens	74-79
25245510-4	2014	One drug, riluzole, which possesses anti-glutamatergic properties, is approved as neuroprotective for ALS.	Riluzole	10-18	superoxide dismutase 1	Homo sapiens	102-105
24356417-0	2014	The neuroprotection exerted by memantine, minocycline and lithium, against neurotoxicity of CSF from patients with amyotrophic lateral sclerosis, is antagonized by riluzole.	Riluzole	164-172	colony stimulating factor 2	Homo sapiens	92-95
23777615-3	2013	Here, we demonstrate that riluzole stimulated glutamate uptake and augmented the expression of the glutamate EAAC1 transporter in C6 astroglial cell cultures.	Riluzole	26-34	solute carrier family 1 member 1	Homo sapiens	109-114
23864030-4	2013	Because riluzole, the only Food and Drug Administration (FDA)-approved treatment, prolongs the ALS patient"s life by only 3 months, new therapeutic agents are urgently needed.	Riluzole	8-16	superoxide dismutase 1	Homo sapiens	95-98
23709339-7	2013	Riluzole attenuated the spatial memory impairment, the elevation of serum cytokines and the decrease in GLT1 gene expression in Aged rats, but had no effect on young rats infused with LPS.	Riluzole	0-8	solute carrier family 1 member 2	Rattus norvegicus	104-108
23777615-4	2013	The effect of riluzole on glutamate uptake was reduced to below controls when it was co-administered with inhibitors of protein kinase C (PKC; bisindolylmaleimide II), phosphatidylinositol 3-kinase (PI3K; wortmannin) and fibroblast growth factor receptor 1 (FGFR1; PD173074).	Riluzole	14-22	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	168-197
23777615-4	2013	The effect of riluzole on glutamate uptake was reduced to below controls when it was co-administered with inhibitors of protein kinase C (PKC; bisindolylmaleimide II), phosphatidylinositol 3-kinase (PI3K; wortmannin) and fibroblast growth factor receptor 1 (FGFR1; PD173074).	Riluzole	14-22	fibroblast growth factor receptor 1	Homo sapiens	221-256
23777615-4	2013	The effect of riluzole on glutamate uptake was reduced to below controls when it was co-administered with inhibitors of protein kinase C (PKC; bisindolylmaleimide II), phosphatidylinositol 3-kinase (PI3K; wortmannin) and fibroblast growth factor receptor 1 (FGFR1; PD173074).	Riluzole	14-22	fibroblast growth factor receptor 1	Homo sapiens	258-263
23707481-5	2013	Specifically, we show that bath application of three different sodium channel blockers-diphenytoin, riluzole, and lidocaine-slow spontaneous CA3 bursts.	Riluzole	100-108	carbonic anhydrase 3	Homo sapiens	141-144
23834207-7	2013	Riluzole leads to AMPK phosphorylation and to the phosphorylation of its downstream target, AS-160.	Riluzole	0-8	TBC1 domain family, member 4	Mus musculus	92-98
23862110-12	2013	CONCLUSION: Changes in the conductance of several potassium channels, including voltage- gated potassium (Kv1, Kv4) and big Ca(2+)-activated K(+) (BK) channels may be responsible for the neuro protective effect of riluzole against 3-AP induced alterations in the firing properties of Purkinje cells in a rat model of ataxia.	Riluzole	214-222	potassium voltage-gated channel subfamily A member 5	Rattus norvegicus	106-109
24038380-8	2013	Only 1 compound, riluzole, is approved by the US Food and Drug Administration for ALS; several therapies are in clinical trials, including 2 mesenchymal stem cell trials.	Riluzole	17-25	superoxide dismutase 1	Homo sapiens	82-85
23862110-12	2013	CONCLUSION: Changes in the conductance of several potassium channels, including voltage- gated potassium (Kv1, Kv4) and big Ca(2+)-activated K(+) (BK) channels may be responsible for the neuro protective effect of riluzole against 3-AP induced alterations in the firing properties of Purkinje cells in a rat model of ataxia.	Riluzole	214-222	potassium voltage-gated channel subfamily A member 4	Rattus norvegicus	111-114
23762454-0	2013	Electrophysiologic biomarkers for assessing disease progression and the effect of riluzole in SOD1 G93A ALS mice.	Riluzole	82-90	superoxide dismutase 1, soluble	Mus musculus	94-98
22527636-0	2013	Microglial SK3 and SK4 currents and activation state are modulated by the neuroprotective drug, riluzole.	Riluzole	96-104	potassium calcium-activated channel subfamily N member 3	Rattus norvegicus	11-14
23517137-5	2013	Afterward, P1 and P3 groups received riluzole (6 (mg/kg) every 12 hours for 7 days.	Riluzole	37-45	crystallin gamma F, pseudogene	Homo sapiens	11-20
23620825-9	2013	We used primary rat microglia and a rat microglial cell line (MLS-9) in which riluzole robustly activates both SK3 and KCa3.1 currents.	Riluzole	78-86	potassium calcium-activated channel subfamily N member 3	Rattus norvegicus	111-114
23620825-9	2013	We used primary rat microglia and a rat microglial cell line (MLS-9) in which riluzole robustly activates both SK3 and KCa3.1 currents.	Riluzole	78-86	potassium calcium-activated channel subfamily N member 4	Rattus norvegicus	119-125
22527636-4	2013	Here, we assessed actions of the neuroprotective drug, riluzole, on two Ca(2+)- activated K channels in microglia - SK3 (KCa2.3, KCNN3) and SK4 (KCa3.1, KCNN4) - and on classical versus alternative microglial activation.	Riluzole	55-63	potassium calcium-activated channel subfamily N member 4	Rattus norvegicus	153-158
22527636-0	2013	Microglial SK3 and SK4 currents and activation state are modulated by the neuroprotective drug, riluzole.	Riluzole	96-104	potassium calcium-activated channel subfamily N member 4	Rattus norvegicus	19-22
22527636-8	2013	Surprisingly then, in whole cell recordings, riluzole rapidly activated SK3 and SK4 channels for as long as it was present, and did not require elevated intracellular Ca(2+).	Riluzole	45-53	potassium calcium-activated channel subfamily N member 3	Rattus norvegicus	72-75
22527636-8	2013	Surprisingly then, in whole cell recordings, riluzole rapidly activated SK3 and SK4 channels for as long as it was present, and did not require elevated intracellular Ca(2+).	Riluzole	45-53	potassium calcium-activated channel subfamily N member 4	Rattus norvegicus	80-83
22527636-10	2013	Riluzole decreased classical LPS-induced activation, and increased some aspects of IL-4-induced alternative activation.	Riluzole	0-8	interleukin 4	Rattus norvegicus	83-87
22527636-4	2013	Here, we assessed actions of the neuroprotective drug, riluzole, on two Ca(2+)- activated K channels in microglia - SK3 (KCa2.3, KCNN3) and SK4 (KCa3.1, KCNN4) - and on classical versus alternative microglial activation.	Riluzole	55-63	potassium calcium-activated channel subfamily N member 3	Rattus norvegicus	116-119
22527636-4	2013	Here, we assessed actions of the neuroprotective drug, riluzole, on two Ca(2+)- activated K channels in microglia - SK3 (KCa2.3, KCNN3) and SK4 (KCa3.1, KCNN4) - and on classical versus alternative microglial activation.	Riluzole	55-63	potassium calcium-activated channel subfamily N member 3	Rattus norvegicus	121-127
22527636-4	2013	Here, we assessed actions of the neuroprotective drug, riluzole, on two Ca(2+)- activated K channels in microglia - SK3 (KCa2.3, KCNN3) and SK4 (KCa3.1, KCNN4) - and on classical versus alternative microglial activation.	Riluzole	55-63	potassium calcium-activated channel subfamily N member 3	Rattus norvegicus	129-134
22527636-4	2013	Here, we assessed actions of the neuroprotective drug, riluzole, on two Ca(2+)- activated K channels in microglia - SK3 (KCa2.3, KCNN3) and SK4 (KCa3.1, KCNN4) - and on classical versus alternative microglial activation.	Riluzole	55-63	potassium calcium-activated channel subfamily N member 4	Rattus norvegicus	140-143
22527636-4	2013	Here, we assessed actions of the neuroprotective drug, riluzole, on two Ca(2+)- activated K channels in microglia - SK3 (KCa2.3, KCNN3) and SK4 (KCa3.1, KCNN4) - and on classical versus alternative microglial activation.	Riluzole	55-63	potassium calcium-activated channel subfamily N member 4	Rattus norvegicus	145-151
22947335-5	2013	Importantly, several drugs that have been evaluated for the treatment of SCI, such as riluzole, are known substrates of Pgp.	Riluzole	86-94	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	120-123
22947335-6	2013	We therefore examined whether Pgp-mediated pharmacoresistance diminishes delivery of riluzole to the injured spinal cord.	Riluzole	85-93	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	30-33
22947335-8	2013	Spinal cord uptake of i.p.-delivered riluzole was significantly reduced following SCI in wild type but not Abcb1a-knockout rats, highlighting a critical role for Pgp in mediating drug resistance following SCI.	Riluzole	37-45	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	162-165
22892214-1	2012	Riluzole (1) is an approved therapeutic for the treatment of ALS and has also demonstrated anti-melanoma activity in metabotropic glutamate GRM1 positive cell lines, a mouse xenograft assay and human clinical trials.	Riluzole	0-8	glutamate receptor, metabotropic 1	Mus musculus	140-144
23185000-7	2012	Despite the role of BDNF in dendritic spine reorganization, deep-layer spine remodeling does not obviously parallel progressive-ratio response patterns, but treatment with the Na(+)-channel inhibitor riluzole reverses corticosteroid-induced motivational deficits and restores prefrontal BDNF expression after corticosterone.	Riluzole	200-208	brain derived neurotrophic factor	Homo sapiens	287-291
23116083-6	2013	Based upon these data, UK and international patent applications have been filed which describe the use of INaP blockers, like ranolazine ("Ranexa") and riluzole ("Rilutex"), as anti-metastatic agents.	Riluzole	152-160	NFKB inhibitor zeta	Homo sapiens	106-110
22995823-0	2012	In silico docking reveals possible Riluzole binding sites on Nav1.6 sodium channel: implications for amyotrophic lateral sclerosis therapy.	Riluzole	35-43	sodium voltage-gated channel alpha subunit 8	Homo sapiens	61-67
22995823-4	2012	Here we predict the structural model of the interaction and report the possible binding sites of Riluzole on Nav1.6 channel.	Riluzole	97-105	sodium voltage-gated channel alpha subunit 8	Homo sapiens	109-115
23185000-7	2012	Despite the role of BDNF in dendritic spine reorganization, deep-layer spine remodeling does not obviously parallel progressive-ratio response patterns, but treatment with the Na(+)-channel inhibitor riluzole reverses corticosteroid-induced motivational deficits and restores prefrontal BDNF expression after corticosterone.	Riluzole	200-208	brain derived neurotrophic factor	Homo sapiens	20-24
22533628-10	2012	Riluzole (10 mum) reversed Tef-stimulated activity of K(Na)  channels.	Riluzole	0-8	thyrotroph embryonic factor	Mus musculus	27-30
22391793-0	2012	The protective effects of riluzole on manganese-induced disruption of glutamate transporters and glutamine synthetase in the cultured astrocytes.	Riluzole	26-34	glutamate-ammonia ligase	Homo sapiens	97-117
22169158-1	2012	BACKGROUND: Although amyotrophic lateral sclerosis (ALS) is a relentlessly progressive disorder, early diagnosis allows a prompt start with the specific drug riluzole and an accurate palliative care planning.	Riluzole	158-166	superoxide dismutase 1	Homo sapiens	52-55
22480308-2	2012	Recent evidence suggests that riluzole can up-regulate the expression and activity of the astrocyte glutamate transporter, GLT-1.	Riluzole	30-38	solute carrier family 1 member 2	Rattus norvegicus	123-128
22480308-8	2012	Riluzole administration did not regulate GLT-1 levels but significantly reduced GFAP levels, in the lesioned striatum.	Riluzole	0-8	glial fibrillary acidic protein	Rattus norvegicus	80-84
21681448-4	2012	mGluR1 inhibitors (Riluzole or BAY36-7620) inhibited the proliferation of triple negative breast cancer cells in a time- and dose-dependent manner and this inhibition correlated with increased apoptosis as demonstrated by increase in PARP cleavage products and Annexin V staining.	Riluzole	19-27	glutamate receptor, metabotropic 1	Mus musculus	0-6
21681448-4	2012	mGluR1 inhibitors (Riluzole or BAY36-7620) inhibited the proliferation of triple negative breast cancer cells in a time- and dose-dependent manner and this inhibition correlated with increased apoptosis as demonstrated by increase in PARP cleavage products and Annexin V staining.	Riluzole	19-27	poly (ADP-ribose) polymerase family, member 1	Mus musculus	234-238
21681448-4	2012	mGluR1 inhibitors (Riluzole or BAY36-7620) inhibited the proliferation of triple negative breast cancer cells in a time- and dose-dependent manner and this inhibition correlated with increased apoptosis as demonstrated by increase in PARP cleavage products and Annexin V staining.	Riluzole	19-27	annexin A5	Mus musculus	261-270
21844014-11	2011	The combination of riluzole with PLX4720 showed lessened efficacy compared with the combination of riluzole and sorafenib in suppressing the growth of GRM1-expressing cells harboring the B-RAF(V600E) mutation.	Riluzole	19-27	glutamate metabotropic receptor 1	Homo sapiens	151-155
21706151-4	2012	The aim of this study is to determine if add-on of GH to riluzole, with an individually regulated dose based on Insulin-like growth factor 1 (IGF-I) production, was able to reduce neuronal loss in the motor cortex, reduce mortality, and improve motor function of ALS patients.	Riluzole	57-65	insulin like growth factor 1	Homo sapiens	112-140
21706151-4	2012	The aim of this study is to determine if add-on of GH to riluzole, with an individually regulated dose based on Insulin-like growth factor 1 (IGF-I) production, was able to reduce neuronal loss in the motor cortex, reduce mortality, and improve motor function of ALS patients.	Riluzole	57-65	insulin like growth factor 1	Homo sapiens	142-147
22080156-0	2012	Riluzole elevates GLT-1 activity and levels in striatal astrocytes.	Riluzole	0-8	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	18-23
22080156-6	2012	The neuroprotective compound riluzole (100 muM) upregulated GLT-1 levels and activity, through a mechanism that was not dependent on blockade of voltage-sensitive ion channels, since zonasimide (1 mM) did not regulate GLT-1.	Riluzole	29-37	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	60-65
22080156-6	2012	The neuroprotective compound riluzole (100 muM) upregulated GLT-1 levels and activity, through a mechanism that was not dependent on blockade of voltage-sensitive ion channels, since zonasimide (1 mM) did not regulate GLT-1.	Riluzole	29-37	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	218-223
23077590-6	2012	Using GSK3 inhibitors and siRNA knock-down, we demonstrate that the mechanism of riluzole-induced Smad phosphorylation involved GSK3beta.	Riluzole	81-89	glycogen synthase kinase 3 beta	Homo sapiens	128-136
23077590-10	2012	We further show that riluzole upregulates the expression of INHBB and PLAU, two genes associated with the TGFbeta signaling pathway.	Riluzole	21-29	inhibin subunit beta B	Homo sapiens	60-65
23077590-10	2012	We further show that riluzole upregulates the expression of INHBB and PLAU, two genes associated with the TGFbeta signaling pathway.	Riluzole	21-29	plasminogen activator, urokinase	Homo sapiens	70-74
23077590-10	2012	We further show that riluzole upregulates the expression of INHBB and PLAU, two genes associated with the TGFbeta signaling pathway.	Riluzole	21-29	transforming growth factor beta 1	Homo sapiens	106-113
21844014-3	2011	We investigate the preclinical efficacy of combining the multikinase inhibitor sorafenib or the mutated B-RAF inhibitor PLX4720 with riluzole, an inhibitor of glutamate release that antagonizes metabotropic glutamate receptor 1 (GRM1) signaling in melanoma cells.	Riluzole	133-141	glutamate metabotropic receptor 1	Homo sapiens	194-227
21844014-3	2011	We investigate the preclinical efficacy of combining the multikinase inhibitor sorafenib or the mutated B-RAF inhibitor PLX4720 with riluzole, an inhibitor of glutamate release that antagonizes metabotropic glutamate receptor 1 (GRM1) signaling in melanoma cells.	Riluzole	133-141	glutamate metabotropic receptor 1	Homo sapiens	229-233
21844014-10	2011	RESULTS: The combination of riluzole with sorafenib exhibited enhanced antitumor activities in GRM1-expressing melanoma cells harboring either wild-type or mutated B-RAF.	Riluzole	28-36	glutamate metabotropic receptor 1	Homo sapiens	95-99
21844014-10	2011	RESULTS: The combination of riluzole with sorafenib exhibited enhanced antitumor activities in GRM1-expressing melanoma cells harboring either wild-type or mutated B-RAF.	Riluzole	28-36	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	164-169
22171093-6	2012	Riluzole at 500 muM was used as a reference agonist.	Riluzole	0-8	latexin	Homo sapiens	16-19
21779782-9	2012	CONCLUSIONS: Riluzole"s therapeutic potential for treating mood disorders may involve GLT-1 and BDNF, and we suggest this protocol could be used to further characterize its precise long-term biochemical mechanisms of action in animal models of depression.	Riluzole	13-21	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	86-91
21779782-9	2012	CONCLUSIONS: Riluzole"s therapeutic potential for treating mood disorders may involve GLT-1 and BDNF, and we suggest this protocol could be used to further characterize its precise long-term biochemical mechanisms of action in animal models of depression.	Riluzole	13-21	brain derived neurotrophic factor	Mus musculus	96-100
22177998-5	2012	We hypothesized that riluzole might block the putative pore-forming subunits of Sur1-regulated NC(Ca-ATP) channels, Trpm4.	Riluzole	21-29	ATP binding cassette subfamily C member 8	Rattus norvegicus	80-84
22177998-5	2012	We hypothesized that riluzole might block the putative pore-forming subunits of Sur1-regulated NC(Ca-ATP) channels, Trpm4.	Riluzole	21-29	transient receptor potential cation channel, subfamily M, member 4	Rattus norvegicus	116-121
22177998-6	2012	In patch clamp experiments, riluzole blocked Sur1-regulated NC(Ca-ATP) channels in endothelial cells and heterologously expressed Trpm4 (IC(50), 31 muM).	Riluzole	28-36	ATP binding cassette subfamily C member 8	Rattus norvegicus	45-49
22177998-6	2012	In patch clamp experiments, riluzole blocked Sur1-regulated NC(Ca-ATP) channels in endothelial cells and heterologously expressed Trpm4 (IC(50), 31 muM).	Riluzole	28-36	transient receptor potential cation channel, subfamily M, member 4	Rattus norvegicus	130-135
22177998-10	2012	We conclude that both drugs act similarly, glibenclamide on the regulatory subunit, and riluzole on the putative pore-forming subunit of the Sur1-regulated NC(Ca-ATP) channel.	Riluzole	88-96	ATP binding cassette subfamily C member 8	Rattus norvegicus	141-145
23077590-2	2012	A phase 0 clinical trial of riluzole as a single agent in patients with melanoma resulted in involution of tumors associated with inhibition of both the mitogen-activated protein kinase (MAPK) and phophoinositide-3-kinase/AKT (PI3K/AKT) pathways in 34% of patients.	Riluzole	28-36	AKT serine/threonine kinase 1	Homo sapiens	222-225
23077590-2	2012	A phase 0 clinical trial of riluzole as a single agent in patients with melanoma resulted in involution of tumors associated with inhibition of both the mitogen-activated protein kinase (MAPK) and phophoinositide-3-kinase/AKT (PI3K/AKT) pathways in 34% of patients.	Riluzole	28-36	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	227-235
23077590-3	2012	In the present study, we demonstrate that riluzole inhibits AKT-mediated glycogen synthase kinase 3 (GSK3) phosphorylation in melanoma cell lines.	Riluzole	42-50	AKT serine/threonine kinase 1	Homo sapiens	60-63
23077590-5	2012	We present evidence that riluzole increases Smad2 and Smad3 linker phosphorylation at the cluster of serines 245/250/255 and serine 204 respectively.	Riluzole	25-33	SMAD family member 2	Homo sapiens	44-49
23077590-5	2012	We present evidence that riluzole increases Smad2 and Smad3 linker phosphorylation at the cluster of serines 245/250/255 and serine 204 respectively.	Riluzole	25-33	SMAD family member 3	Homo sapiens	54-59
21844014-11	2011	The combination of riluzole with PLX4720 showed lessened efficacy compared with the combination of riluzole and sorafenib in suppressing the growth of GRM1-expressing cells harboring the B-RAF(V600E) mutation.	Riluzole	19-27	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	187-192
21844014-12	2011	CONCLUSIONS: The combination of riluzole with sorafenib seems potent in suppressing tumor proliferation in vitro and in vivo in GRM1-expressing melanoma cells regardless of B-RAF genotype and may be a viable therapeutic clinical combination.	Riluzole	32-40	glutamate metabotropic receptor 1	Homo sapiens	128-132
21295555-0	2011	Riluzole-induced glial cell line-derived neurotrophic factor production is regulated through fibroblast growth factor receptor signaling in rat C6 glioma cells.	Riluzole	0-8	glial cell derived neurotrophic factor	Rattus norvegicus	17-60
21788423-0	2011	Inhibition of Navbeta4 peptide-mediated resurgent sodium currents in Nav1.7 channels by carbamazepine, riluzole, and anandamide.	Riluzole	103-111	sodium voltage-gated channel beta subunit 4	Homo sapiens	14-22
21788423-0	2011	Inhibition of Navbeta4 peptide-mediated resurgent sodium currents in Nav1.7 channels by carbamazepine, riluzole, and anandamide.	Riluzole	103-111	sodium voltage-gated channel alpha subunit 9	Homo sapiens	69-75
21796043-8	2011	Drug therapy for ALS is currently limited to riluzole; however, patients may be treated with a number of nonpharmacologic methods on the basis of their symptoms.	Riluzole	45-53	superoxide dismutase 1	Homo sapiens	17-20
21295555-3	2011	This study investigated the mechanism of riluzole-induced glial cell line-derived neurotrophic factor (GDNF) production in rat C6 glioma cells (C6 cells), a model of astrocytes.	Riluzole	41-49	glial cell derived neurotrophic factor	Rattus norvegicus	58-101
21295555-3	2011	This study investigated the mechanism of riluzole-induced glial cell line-derived neurotrophic factor (GDNF) production in rat C6 glioma cells (C6 cells), a model of astrocytes.	Riluzole	41-49	glial cell derived neurotrophic factor	Rattus norvegicus	103-107
21295555-4	2011	The study investigated the phosphorylation of cAMP response element binding protein (CREB), an important transcriptional factor of the gdnf gene, and found that riluzole increased CREB phosphorylation in a time-dependent manner, peaking at 40min after treatment.	Riluzole	161-169	cAMP responsive element binding protein 1	Rattus norvegicus	46-83
21295555-4	2011	The study investigated the phosphorylation of cAMP response element binding protein (CREB), an important transcriptional factor of the gdnf gene, and found that riluzole increased CREB phosphorylation in a time-dependent manner, peaking at 40min after treatment.	Riluzole	161-169	cAMP responsive element binding protein 1	Rattus norvegicus	85-89
21295555-4	2011	The study investigated the phosphorylation of cAMP response element binding protein (CREB), an important transcriptional factor of the gdnf gene, and found that riluzole increased CREB phosphorylation in a time-dependent manner, peaking at 40min after treatment.	Riluzole	161-169	glial cell derived neurotrophic factor	Rattus norvegicus	135-139
21295555-4	2011	The study investigated the phosphorylation of cAMP response element binding protein (CREB), an important transcriptional factor of the gdnf gene, and found that riluzole increased CREB phosphorylation in a time-dependent manner, peaking at 40min after treatment.	Riluzole	161-169	cAMP responsive element binding protein 1	Rattus norvegicus	180-184
21295555-5	2011	The riluzole-induced CREB phosphorylation was completely blocked by a mitogen-activated protein kinase kinase (MEK) inhibitor (U0126).	Riluzole	4-12	cAMP responsive element binding protein 1	Rattus norvegicus	21-25
21295555-6	2011	Riluzole increased extracellular signal-regulated kinase (ERK) activation prior to CREB phosphorylation.	Riluzole	0-8	Eph receptor B1	Rattus norvegicus	19-56
21295555-6	2011	Riluzole increased extracellular signal-regulated kinase (ERK) activation prior to CREB phosphorylation.	Riluzole	0-8	Eph receptor B1	Rattus norvegicus	58-61
21295555-7	2011	These results suggest that riluzole rapidly activates the MEK/ERK/CREB pathway.	Riluzole	27-35	Eph receptor B1	Rattus norvegicus	62-65
21295555-7	2011	These results suggest that riluzole rapidly activates the MEK/ERK/CREB pathway.	Riluzole	27-35	cAMP responsive element binding protein 1	Rattus norvegicus	66-70
21295555-8	2011	Furthermore, two types of fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors (SU5402 and PD173074) completely blocked riluzole-induced CREB phosphorylation.	Riluzole	135-143	cAMP responsive element binding protein 1	Rattus norvegicus	152-156
21295555-10	2011	These findings suggest that riluzole induces CREB phosphorylation through FGFR.	Riluzole	28-36	cAMP responsive element binding protein 1	Rattus norvegicus	45-49
21295555-11	2011	In addition, PD173074 inhibited riluzole-induced GDNF production.	Riluzole	32-40	glial cell derived neurotrophic factor	Rattus norvegicus	49-53
21295555-13	2011	These findings suggest that riluzole rapidly activates a MEK/ERK/CREB pathway through FGFR in a glutamate transporter-independent manner, followed by GDNF expression in C6 cells.	Riluzole	28-36	Eph receptor B1	Rattus norvegicus	61-64
21295555-13	2011	These findings suggest that riluzole rapidly activates a MEK/ERK/CREB pathway through FGFR in a glutamate transporter-independent manner, followed by GDNF expression in C6 cells.	Riluzole	28-36	cAMP responsive element binding protein 1	Rattus norvegicus	65-69
21295555-13	2011	These findings suggest that riluzole rapidly activates a MEK/ERK/CREB pathway through FGFR in a glutamate transporter-independent manner, followed by GDNF expression in C6 cells.	Riluzole	28-36	glial cell derived neurotrophic factor	Rattus norvegicus	150-154
21325066-0	2011	Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo.	Riluzole	0-8	glutamate metabotropic receptor 1	Homo sapiens	107-140
21325066-2	2011	Our group has previously shown that human GRM1 (hGRM1) expressing melanoma cells release excess extracellular glutamate and are growth inhibited by riluzole, an inhibitor of glutamate release.	Riluzole	148-156	glutamate metabotropic receptor 1	Homo sapiens	42-46
21325066-2	2011	Our group has previously shown that human GRM1 (hGRM1) expressing melanoma cells release excess extracellular glutamate and are growth inhibited by riluzole, an inhibitor of glutamate release.	Riluzole	148-156	glutamate metabotropic receptor 1	Homo sapiens	48-53
21325066-9	2011	RESULTS: In the hGRM1-positive cell lines C8161 and UACC903, riluzole enhanced the lethal effects of ionizing radiation; no difference was seen in the hGRM1-negative UACC930 cell line.	Riluzole	61-69	glutamate metabotropic receptor 1	Homo sapiens	16-21
21325066-10	2011	C8161 cells treated with riluzole plus irradiation also showed the highest levels of the cleaved forms of PARP and caspase-3; excised C8161 xenografts showed the greatest number of apoptotic cells by immunohistochemistry (P &lt; 0.001).	Riluzole	25-33	poly(ADP-ribose) polymerase 1	Homo sapiens	106-110
21325066-10	2011	C8161 cells treated with riluzole plus irradiation also showed the highest levels of the cleaved forms of PARP and caspase-3; excised C8161 xenografts showed the greatest number of apoptotic cells by immunohistochemistry (P &lt; 0.001).	Riluzole	25-33	caspase 3	Homo sapiens	115-124
21059347-14	2011	Riluzole use was associated with significant correction in ERK activation time in all subjects (mean change from 3.82+-0.27 (baseline) to 2.99+-0.26 (endpoint) minutes; p=0.007).	Riluzole	0-8	mitogen-activated protein kinase 1	Homo sapiens	59-62
21098017-0	2011	Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival.	Riluzole	21-29	heat shock factor 1	Mus musculus	44-63
21115851-8	2011	Openers of small- and intermediate-conductance Ca(2+)-activated potassium channels known to interact with calmodulin, such as 1-EBIO, DCEBIO, or riluzole, also activated TMEM16A.	Riluzole	145-153	calmodulin 2	Mus musculus	106-116
21115851-8	2011	Openers of small- and intermediate-conductance Ca(2+)-activated potassium channels known to interact with calmodulin, such as 1-EBIO, DCEBIO, or riluzole, also activated TMEM16A.	Riluzole	145-153	anoctamin 1, calcium activated chloride channel	Mus musculus	170-177
21324003-6	2011	Riluzole (5 muM; applied 15 min after TBOA) inhibited bursting, decreased the frequency of spontaneous glutamatergic events, reversed changes in S100B immunostaining and prevented late loss of motoneuron staining.	Riluzole	0-8	S100 calcium binding protein B	Rattus norvegicus	145-150
21786535-5	2011	The t-BHP-induced increase of I(Na(NI)) was reversed by a further application of riluzole (10 microM) or oxcarbazepine (10 microM).	Riluzole	81-89	internexin neuronal intermediate filament protein, alpha	Mus musculus	30-38
21098017-0	2011	Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival.	Riluzole	21-29	heat shock factor 1	Mus musculus	65-69
21098017-0	2011	Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival.	Riluzole	21-29	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	76-99
21098017-0	2011	Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival.	Riluzole	21-29	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	101-105
21098017-2	2011	We show that the neuroprotective drug riluzole increased the amount of HSF1 in NG108-15 neuroprogenitor cells by slowing the specific turnover of HSF1 and supporting a more robust and sustained activation of HSF1.	Riluzole	38-46	heat shock factor 1	Mus musculus	71-75
21098017-2	2011	We show that the neuroprotective drug riluzole increased the amount of HSF1 in NG108-15 neuroprogenitor cells by slowing the specific turnover of HSF1 and supporting a more robust and sustained activation of HSF1.	Riluzole	38-46	heat shock factor 1	Mus musculus	146-150
21098017-2	2011	We show that the neuroprotective drug riluzole increased the amount of HSF1 in NG108-15 neuroprogenitor cells by slowing the specific turnover of HSF1 and supporting a more robust and sustained activation of HSF1.	Riluzole	38-46	heat shock factor 1	Mus musculus	146-150
21098017-3	2011	Using Hsp70-luciferase as a functional readout of the activity of HSF1, we show that riluzole amplified the heat shock induction of the reporter gene with an optimal increase at 1 muM.	Riluzole	85-93	heat shock protein 1B	Mus musculus	6-11
21098017-3	2011	Using Hsp70-luciferase as a functional readout of the activity of HSF1, we show that riluzole amplified the heat shock induction of the reporter gene with an optimal increase at 1 muM.	Riluzole	85-93	heat shock factor 1	Mus musculus	66-70
21098017-4	2011	Immunocytochemical staining and Western blot quantitation of HSP70 in NG108-15 neuroprogenitor cells and embryonic spinal cord neurons provided corroborative evidence that riluzole amplified the HSF1-dependent regulation of HSP70 expression.	Riluzole	172-180	heat shock protein 1B	Mus musculus	61-66
21098017-4	2011	Immunocytochemical staining and Western blot quantitation of HSP70 in NG108-15 neuroprogenitor cells and embryonic spinal cord neurons provided corroborative evidence that riluzole amplified the HSF1-dependent regulation of HSP70 expression.	Riluzole	172-180	heat shock factor 1	Mus musculus	195-199
21098017-4	2011	Immunocytochemical staining and Western blot quantitation of HSP70 in NG108-15 neuroprogenitor cells and embryonic spinal cord neurons provided corroborative evidence that riluzole amplified the HSF1-dependent regulation of HSP70 expression.	Riluzole	172-180	heat shock protein 1B	Mus musculus	224-229
21098017-5	2011	Parallel studies on the GLT1 glutamate transporter showed that riluzole increased GLT1-reporter and GLT1 protein expression and that the increase was enhanced by heat shock and coincident with the increased expression of HSP70 and HSP90.	Riluzole	63-71	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	24-28
21098017-5	2011	Parallel studies on the GLT1 glutamate transporter showed that riluzole increased GLT1-reporter and GLT1 protein expression and that the increase was enhanced by heat shock and coincident with the increased expression of HSP70 and HSP90.	Riluzole	63-71	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	82-86
21098017-5	2011	Parallel studies on the GLT1 glutamate transporter showed that riluzole increased GLT1-reporter and GLT1 protein expression and that the increase was enhanced by heat shock and coincident with the increased expression of HSP70 and HSP90.	Riluzole	63-71	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	82-86
21098017-5	2011	Parallel studies on the GLT1 glutamate transporter showed that riluzole increased GLT1-reporter and GLT1 protein expression and that the increase was enhanced by heat shock and coincident with the increased expression of HSP70 and HSP90.	Riluzole	63-71	heat shock protein 1B	Mus musculus	221-226
21098017-5	2011	Parallel studies on the GLT1 glutamate transporter showed that riluzole increased GLT1-reporter and GLT1 protein expression and that the increase was enhanced by heat shock and coincident with the increased expression of HSP70 and HSP90.	Riluzole	63-71	heat shock protein 86, pseudogene 1	Mus musculus	231-236
21098017-6	2011	This result is consistent with the anti-glutamatergic profile of riluzole and the presence of multiple heat shock elements on the GLT1 gene promoter, suggesting that riluzole may modulate GLT1 expression through HSF1.	Riluzole	166-174	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	130-134
21098017-6	2011	This result is consistent with the anti-glutamatergic profile of riluzole and the presence of multiple heat shock elements on the GLT1 gene promoter, suggesting that riluzole may modulate GLT1 expression through HSF1.	Riluzole	166-174	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	188-192
21098017-6	2011	This result is consistent with the anti-glutamatergic profile of riluzole and the presence of multiple heat shock elements on the GLT1 gene promoter, suggesting that riluzole may modulate GLT1 expression through HSF1.	Riluzole	166-174	heat shock factor 1	Mus musculus	212-216
21098017-8	2011	In summary, we show that riluzole increased the amount and activity of HSF1 to boost the expression of HSPs and GLT1 for neuroprotection under stress.	Riluzole	25-33	heat shock factor 1	Mus musculus	71-75
21098017-8	2011	In summary, we show that riluzole increased the amount and activity of HSF1 to boost the expression of HSPs and GLT1 for neuroprotection under stress.	Riluzole	25-33	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	112-116
20576613-5	2010	On the other hand, the glutamate signaling inhibitors riluzole and (+)-MK801 maleate suppressed the alkaline phosphatase activities and mineralized nodule formation during the cytodifferentiation and mineralization.	Riluzole	54-62	alkaline phosphatase, placental	Homo sapiens	100-120
21857080-8	2011	The levels of the anti-apoptotic proteins Bcl-2 and HSP70 were higher in the riluzole groups than in the control.	Riluzole	77-85	BCL2, apoptosis regulator	Rattus norvegicus	42-47
21857080-8	2011	The levels of the anti-apoptotic proteins Bcl-2 and HSP70 were higher in the riluzole groups than in the control.	Riluzole	77-85	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	52-57
21857080-9	2011	Furthermore, co-administration of riluzole with morphine significantly decreased caspase-3 protein levels and glutamate content of the cerebral cortex compared with the control.	Riluzole	34-42	caspase 3	Rattus norvegicus	81-90
20942785-3	2010	The only drug that is available to treat ALS is riluzole, which extends survival by just 2-3 months.	Riluzole	48-56	superoxide dismutase 1	Homo sapiens	41-44
21095567-0	2010	Chemical-genetic screen identifies riluzole as an enhancer of Wnt/beta-catenin signaling in melanoma.	Riluzole	35-43	catenin beta 1	Homo sapiens	66-78
21095567-3	2010	We found that treating melanoma cells with riluzole in vitro enhances the ability of WNT3A to regulate gene expression, to promote pigmentation, and to decrease cell proliferation.	Riluzole	43-51	Wnt family member 3A	Homo sapiens	85-90
21095567-5	2010	Interestingly, siRNAs targeting the metabotropic glutamate receptor, GRM1, a reported indirect target of riluzole, enhance beta-catenin signaling.	Riluzole	105-113	glutamate metabotropic receptor 1	Homo sapiens	69-73
21095567-5	2010	Interestingly, siRNAs targeting the metabotropic glutamate receptor, GRM1, a reported indirect target of riluzole, enhance beta-catenin signaling.	Riluzole	105-113	catenin beta 1	Homo sapiens	123-135
21095567-6	2010	The unexpected regulation of beta-catenin signaling by both riluzole and GRM1 has implications for the future uses of this drug.	Riluzole	60-68	catenin beta 1	Homo sapiens	29-41
20505744-3	2010	Using the glutamate-release inhibitor Riluzole or the non-competitive GRM1 antagonist BAY 36-7620 we were able to induce considerable inhibition of colony formation and invasion in GRM1-expressing melanoma lines.	Riluzole	38-46	glutamate metabotropic receptor 1	Homo sapiens	181-185
18825147-8	2010	Riluzole treatment also reversed CUS-induced reductions in glial metabolism and GFAP mRNA expression.	Riluzole	0-8	glial fibrillary acidic protein	Rattus norvegicus	80-84
23637674-6	2010	The P1 and P3 groups then received 6 mg/kg of riluzole intraperitoneally every 12 hours for 7 days.	Riluzole	46-54	perforin 1	Rattus norvegicus	4-13
20074625-5	2010	Riluzole was found to enhance neurite branching in both CGRP and IB4 positive neurons compared to vehicle treated cultures.	Riluzole	0-8	calcitonin-related polypeptide alpha	Rattus norvegicus	56-60
20074625-6	2010	However, neurite length was only significantly increased in CGRP positive neurons in riluzole treated cultures.	Riluzole	85-93	calcitonin-related polypeptide alpha	Rattus norvegicus	60-64
19524026-5	2009	Recently, we have found that riluzole, which blocks voltage-gated sodium channels and thereby reduces glutamate release, actually strengthens immunoreactivity of BDNF in hippocampal granule neurons of rats.	Riluzole	29-37	brain-derived neurotrophic factor	Rattus norvegicus	162-166
20059984-5	2010	In brainstem slices from normal rats, riluzole increased phosphorylated cAMP response element binding protein (pCREB) expressing nuclei in dopamine-beta-hydroxylase (DbetaH) containing cells in the LC.	Riluzole	38-46	dopamine beta-hydroxylase	Rattus norvegicus	139-164
20823560-5	2010	In our study, the combination of SF with riluzole not only stimulates the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), reduced nicotinamide adenine dinucleotide phosphate (NADPH): quinone oxidoreductase 1 (NQO1) and heme oxygenase 1 (HO-1), but also reduces the extracellular accumulation of glutamate.	Riluzole	41-49	NFE2 like bZIP transcription factor 2	Rattus norvegicus	88-131
20823560-5	2010	In our study, the combination of SF with riluzole not only stimulates the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), reduced nicotinamide adenine dinucleotide phosphate (NADPH): quinone oxidoreductase 1 (NQO1) and heme oxygenase 1 (HO-1), but also reduces the extracellular accumulation of glutamate.	Riluzole	41-49	NFE2 like bZIP transcription factor 2	Rattus norvegicus	133-137
20823560-5	2010	In our study, the combination of SF with riluzole not only stimulates the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), reduced nicotinamide adenine dinucleotide phosphate (NADPH): quinone oxidoreductase 1 (NQO1) and heme oxygenase 1 (HO-1), but also reduces the extracellular accumulation of glutamate.	Riluzole	41-49	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	227-231
20823560-5	2010	In our study, the combination of SF with riluzole not only stimulates the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), reduced nicotinamide adenine dinucleotide phosphate (NADPH): quinone oxidoreductase 1 (NQO1) and heme oxygenase 1 (HO-1), but also reduces the extracellular accumulation of glutamate.	Riluzole	41-49	heme oxygenase 1	Rattus norvegicus	237-253
20138122-8	2010	Consistent with this, P-gp function was also increased by 1.5-fold and riluzole brain disposition was decreased by 1.7-fold in mSOD1 mice.	Riluzole	71-79	superoxide dismutase 1, soluble	Mus musculus	127-132
20051697-3	2010	METHODS: The patch-clamp technique was used combining an ultrafast solution exchange system to investigate the interaction of riluzole and phenobarbital with recombinant AMPA-type glutamate receptor channels (homomeric GluR2flipGQ or nondesensitizing GluR2L504Y).	Riluzole	126-134	glutamate ionotropic receptor AMPA type subunit 2	Homo sapiens	219-224
19524026-6	2009	Therefore, we examined the riluzole-activated signaling pathways for BDNF production.	Riluzole	27-35	brain-derived neurotrophic factor	Rattus norvegicus	69-73
19524026-7	2009	Riluzole increased levels of phospho-p38 mitogen-activated protein kinase (p38 MAPK), as well as BDNF levels.	Riluzole	0-8	mitogen activated protein kinase 14	Rattus norvegicus	37-40
19524026-7	2009	Riluzole increased levels of phospho-p38 mitogen-activated protein kinase (p38 MAPK), as well as BDNF levels.	Riluzole	0-8	mitogen activated protein kinase 14	Rattus norvegicus	75-78
19524026-8	2009	Inhibition of p38 MAPK by SB203580 reduced riluzole effects, while activation of p38 MAPK by anisomycin increased levels of BDNF, suggesting that p38 MAPK can mediate BDNF production.	Riluzole	43-51	mitogen activated protein kinase 14	Rattus norvegicus	14-17
19524026-9	2009	Riluzole-induced elevation of phospho-activating transcription factor-2, a transcription factor downstream of p38 MAPK, was also observed.	Riluzole	0-8	mitogen activated protein kinase 14	Rattus norvegicus	110-113
19524026-10	2009	A blocker of N-type voltage-gated calcium channels reduced the effects of riluzole on BDNF production and p38 MAPK activation.	Riluzole	74-82	brain-derived neurotrophic factor	Rattus norvegicus	86-90
19524026-12	2009	An A1 receptor agonist inhibited riluzole-induced elevation of BDNF levels, whereas an antagonist not only increased levels of BDNF and active p38 MAPK but also augmented riluzole effects.	Riluzole	33-41	brain-derived neurotrophic factor	Rattus norvegicus	63-67
19528481-4	2009	The activities of caspase-3, -8 and -9 were significantly increased, and caspase inhibitors for caspase-3, -8 and -9 significantly rescued the cell viability of both carcinoma cell lines treated with riluzole.	Riluzole	200-208	caspase 3	Homo sapiens	18-38
19280185-9	2009	Finally, BDNF and transforming growth factor beta-1 serum levels were significantly higher in patients treated with riluzole.	Riluzole	116-124	brain derived neurotrophic factor	Homo sapiens	9-13
19280185-9	2009	Finally, BDNF and transforming growth factor beta-1 serum levels were significantly higher in patients treated with riluzole.	Riluzole	116-124	transforming growth factor beta 1	Homo sapiens	18-51
19458050-3	2009	Furthermore, a xenograft model of melanoma treated with riluzole, an oral GRM1 blocking agent, showed decreased tumor growth compared with the untreated controls.	Riluzole	56-64	glutamate metabotropic receptor 1	Homo sapiens	74-78
19458050-11	2009	CONCLUSIONS: Our data show that glutamate blockade with riluzole can inhibit signaling through the mitogen-activated protein kinase and phosphatidylinositol 3-kinase/AKT pathways and suppress the metabolic activity of melanoma.	Riluzole	56-64	AKT serine/threonine kinase 1	Homo sapiens	166-169
19280185-2	2009	Riluzole interferes with glutamatergic neurotransmission, thereby reducing excitotoxicity, enhancing neurite formation in damaged motoneurons and increasing serum concentrations of BDNF, a brain cortex neurotrophin protecting striatal neurons from degeneration.	Riluzole	0-8	brain derived neurotrophic factor	Homo sapiens	181-185
19528481-4	2009	The activities of caspase-3, -8 and -9 were significantly increased, and caspase inhibitors for caspase-3, -8 and -9 significantly rescued the cell viability of both carcinoma cell lines treated with riluzole.	Riluzole	200-208	caspase 3	Homo sapiens	96-116
19528481-6	2009	Riluzole significantly induced elevation of caspase-4 activity, fluorescence indicating cytosolic calcium, and morphological changes in endoplasmic reticulum (ER) as observed by transmission electron microscopy.	Riluzole	0-8	caspase 4	Homo sapiens	44-53
19378468-11	2009	Tef-induced inward currents were suppressed after further application of tetrodotoxin, riluzole or ranolazine.	Riluzole	87-95	TEF transcription factor, PAR bZIP family member	Rattus norvegicus	0-3
19195673-6	2009	The immunomodulatory effect of riluzole-sensitized cells was ascribed to endogenous type I interferon (IFN) derived from monocytes.	Riluzole	31-39	interferon alpha 1	Homo sapiens	84-107
18618304-8	2009	Riluzole/NaPB administration increased acetylation at H4 and increased NF-kappaB p50 translocation to the nucleus in G93A mice, consistent with a therapeutic effect.	Riluzole	0-8	N-ethylmaleimide sensitive fusion protein attachment protein beta	Mus musculus	9-13
18618304-8	2009	Riluzole/NaPB administration increased acetylation at H4 and increased NF-kappaB p50 translocation to the nucleus in G93A mice, consistent with a therapeutic effect.	Riluzole	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	71-84
19146924-0	2009	Interactions between riluzole and ABCG2/BCRP transporter.	Riluzole	21-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	34-39
19146924-0	2009	Interactions between riluzole and ABCG2/BCRP transporter.	Riluzole	21-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	40-44
19146924-4	2009	We have investigated riluzole as a breast cancer resistance protein (BCRP) substrate by studying its brain transport in CF1 mdr1a (-/-) mice and its intracellular uptake on BeWo cells (human placental choriocarcinoma cell line).	Riluzole	21-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-67
19146924-4	2009	We have investigated riluzole as a breast cancer resistance protein (BCRP) substrate by studying its brain transport in CF1 mdr1a (-/-) mice and its intracellular uptake on BeWo cells (human placental choriocarcinoma cell line).	Riluzole	21-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	69-73
19146924-4	2009	We have investigated riluzole as a breast cancer resistance protein (BCRP) substrate by studying its brain transport in CF1 mdr1a (-/-) mice and its intracellular uptake on BeWo cells (human placental choriocarcinoma cell line).	Riluzole	21-29	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	124-129
19146924-5	2009	We have also investigated the effect of riluzole on BCRP expression level and on its activity using the prazocin as a test probe for brain transport and intracellular uptake.	Riluzole	40-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	52-56
19146924-6	2009	Assays on mdr1a (-/-) mice and BeWo cells showed a higher uptake of riluzole when pretreated with a BCRP inhibitor.	Riluzole	68-76	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	10-15
19146924-6	2009	Assays on mdr1a (-/-) mice and BeWo cells showed a higher uptake of riluzole when pretreated with a BCRP inhibitor.	Riluzole	68-76	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	100-104
19146924-7	2009	After repeated doses of riluzole, BCRP activity was increased in CF1 mdr1a (-/-) mice, riluzole uptake was decrease and both BCRP expression and activity were increased in BeWo cells.	Riluzole	24-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
19146924-7	2009	After repeated doses of riluzole, BCRP activity was increased in CF1 mdr1a (-/-) mice, riluzole uptake was decrease and both BCRP expression and activity were increased in BeWo cells.	Riluzole	24-32	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	69-74
19146924-7	2009	After repeated doses of riluzole, BCRP activity was increased in CF1 mdr1a (-/-) mice, riluzole uptake was decrease and both BCRP expression and activity were increased in BeWo cells.	Riluzole	24-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	125-129
19146924-8	2009	In conclusion, we report in this study that riluzole is transported by BCRP at the BBB level and can enhance its function.	Riluzole	44-52	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	71-75
18445055-9	2008	As riluzole is a protein kinase C (PKC) inhibitor, the PKC antagonist chelerythrine (2.5 microm) mimicked the effect of riluzole and prevented it.	Riluzole	3-11	protein kinase C, gamma	Rattus norvegicus	17-33
18955585-3	2009	Here, we used the neuroprotectant riluzole as a template for the design of KCa2/3 channel activators that are potent enough for in vivo studies.	Riluzole	34-42	potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3	Mus musculus	75-81
18682744-0	2008	Riluzole increases the amount of latent HSF1 for an amplified heat shock response and cytoprotection.	Riluzole	0-8	heat shock transcription factor 1	Homo sapiens	40-44
18682744-4	2008	Immuno-Western and -cytochemical analysis of HSF1 show that riluzole increased the amount of cytosolic HSF1 to afford a greater activation of HSF1 upon heat shock.	Riluzole	60-68	heat shock transcription factor 1	Homo sapiens	45-49
18682744-4	2008	Immuno-Western and -cytochemical analysis of HSF1 show that riluzole increased the amount of cytosolic HSF1 to afford a greater activation of HSF1 upon heat shock.	Riluzole	60-68	heat shock transcription factor 1	Homo sapiens	103-107
18682744-4	2008	Immuno-Western and -cytochemical analysis of HSF1 show that riluzole increased the amount of cytosolic HSF1 to afford a greater activation of HSF1 upon heat shock.	Riluzole	60-68	heat shock transcription factor 1	Homo sapiens	103-107
18682744-5	2008	The increased HSF1 contributed centrally to the cytoprotective activity of riluzole as hsf1 gene knockout negated the synergistic activity of riluzole and conditioning heat shock to confer cell survival under oxidative stress.	Riluzole	75-83	heat shock transcription factor 1	Homo sapiens	14-18
18682744-5	2008	The increased HSF1 contributed centrally to the cytoprotective activity of riluzole as hsf1 gene knockout negated the synergistic activity of riluzole and conditioning heat shock to confer cell survival under oxidative stress.	Riluzole	75-83	heat shock transcription factor 1	Homo sapiens	87-91
18682744-5	2008	The increased HSF1 contributed centrally to the cytoprotective activity of riluzole as hsf1 gene knockout negated the synergistic activity of riluzole and conditioning heat shock to confer cell survival under oxidative stress.	Riluzole	142-150	heat shock transcription factor 1	Homo sapiens	14-18
18682744-5	2008	The increased HSF1 contributed centrally to the cytoprotective activity of riluzole as hsf1 gene knockout negated the synergistic activity of riluzole and conditioning heat shock to confer cell survival under oxidative stress.	Riluzole	142-150	heat shock transcription factor 1	Homo sapiens	87-91
18682744-6	2008	Evidence of a post-transcriptional mechanism for the increase in HSF1 include: quantitation of mRNA(hsf1) by RT-PCR showed no effect of either heat shock or riluzole treatment; riluzole also increased the expression of HSF1 from a CMV-promoter; analysis of the turnover of HSF1 by pulse chase and immunoprecipitation show that riluzole slowed the decay of [(35)S]labeled-HSF1.	Riluzole	177-185	heat shock transcription factor 1	Homo sapiens	65-69
18682744-6	2008	Evidence of a post-transcriptional mechanism for the increase in HSF1 include: quantitation of mRNA(hsf1) by RT-PCR showed no effect of either heat shock or riluzole treatment; riluzole also increased the expression of HSF1 from a CMV-promoter; analysis of the turnover of HSF1 by pulse chase and immunoprecipitation show that riluzole slowed the decay of [(35)S]labeled-HSF1.	Riluzole	177-185	heat shock transcription factor 1	Homo sapiens	219-223
18682744-6	2008	Evidence of a post-transcriptional mechanism for the increase in HSF1 include: quantitation of mRNA(hsf1) by RT-PCR showed no effect of either heat shock or riluzole treatment; riluzole also increased the expression of HSF1 from a CMV-promoter; analysis of the turnover of HSF1 by pulse chase and immunoprecipitation show that riluzole slowed the decay of [(35)S]labeled-HSF1.	Riluzole	177-185	heat shock transcription factor 1	Homo sapiens	219-223
18682744-6	2008	Evidence of a post-transcriptional mechanism for the increase in HSF1 include: quantitation of mRNA(hsf1) by RT-PCR showed no effect of either heat shock or riluzole treatment; riluzole also increased the expression of HSF1 from a CMV-promoter; analysis of the turnover of HSF1 by pulse chase and immunoprecipitation show that riluzole slowed the decay of [(35)S]labeled-HSF1.	Riluzole	177-185	heat shock transcription factor 1	Homo sapiens	219-223
18539273-5	2008	In addition, differentiation was shown to endow the cells with the capacity to respond to riluzole which triggers a robust up-regulation of the GDNF production.	Riluzole	90-98	glial cell derived neurotrophic factor	Rattus norvegicus	144-148
18339646-7	2008	K+ outward currents displaying the characteristics of TREK-1 were observed following various TREK-1-activating stimuli such as membrane stretch, intracellular acidosis, polyunsaturated fatty acids, isoflurane (ISOFL), riluzole, and acetylcholine (ACh).	Riluzole	218-226	potassium channel, subfamily K, member 2	Mus musculus	54-60
18854198-7	2009	However, MK-801 (0.5 mg/kg) induced hyperalgesia and increased the CSF EAAs levels; both effects were prevented by guanosine, riluzole or morphine.	Riluzole	126-134	colony stimulating factor 2	Rattus norvegicus	67-70
19754423-5	2009	Typical CYP1A2 substrates generally contain planar ring that can fit the narrow and planar active site of the enzyme, such as propranolol, clozapine, guanabenz, flutamide, imatinib, thalidomide, carbamazepine, lidocaine, theophylline, tacrine, tizanidine, zolpidem, riluzole, zileuton, and leflunomide.	Riluzole	266-274	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	8-14
19966906-2	2009	Currently, the management of ALS is essentially symptoms-based, and riluzole, an antiglutamatergic agent, is the only drug for the treatment of ALS approved by the food and drug administration.	Riluzole	68-76	superoxide dismutase 1	Homo sapiens	144-147
19966906-7	2009	CONCLUSIONS: Riluzole is the only compound that demonstrated a beneficial effect on ALS patients, but with only modest increase in survival.	Riluzole	13-21	superoxide dismutase 1	Homo sapiens	84-87
18716217-5	2008	Putative CPG interneurons such as commissural and Hb9 interneurons also expressed I(NaP)-dependent (riluzole-sensitive) bursting properties.	Riluzole	100-108	motor neuron and pancreas homeobox 1	Homo sapiens	50-53
18682744-6	2008	Evidence of a post-transcriptional mechanism for the increase in HSF1 include: quantitation of mRNA(hsf1) by RT-PCR showed no effect of either heat shock or riluzole treatment; riluzole also increased the expression of HSF1 from a CMV-promoter; analysis of the turnover of HSF1 by pulse chase and immunoprecipitation show that riluzole slowed the decay of [(35)S]labeled-HSF1.	Riluzole	177-185	heat shock transcription factor 1	Homo sapiens	65-69
18682744-6	2008	Evidence of a post-transcriptional mechanism for the increase in HSF1 include: quantitation of mRNA(hsf1) by RT-PCR showed no effect of either heat shock or riluzole treatment; riluzole also increased the expression of HSF1 from a CMV-promoter; analysis of the turnover of HSF1 by pulse chase and immunoprecipitation show that riluzole slowed the decay of [(35)S]labeled-HSF1.	Riluzole	177-185	heat shock transcription factor 1	Homo sapiens	219-223
18682744-6	2008	Evidence of a post-transcriptional mechanism for the increase in HSF1 include: quantitation of mRNA(hsf1) by RT-PCR showed no effect of either heat shock or riluzole treatment; riluzole also increased the expression of HSF1 from a CMV-promoter; analysis of the turnover of HSF1 by pulse chase and immunoprecipitation show that riluzole slowed the decay of [(35)S]labeled-HSF1.	Riluzole	177-185	heat shock transcription factor 1	Homo sapiens	219-223
18682744-6	2008	Evidence of a post-transcriptional mechanism for the increase in HSF1 include: quantitation of mRNA(hsf1) by RT-PCR showed no effect of either heat shock or riluzole treatment; riluzole also increased the expression of HSF1 from a CMV-promoter; analysis of the turnover of HSF1 by pulse chase and immunoprecipitation show that riluzole slowed the decay of [(35)S]labeled-HSF1.	Riluzole	177-185	heat shock transcription factor 1	Homo sapiens	219-223
18682744-7	2008	The effect of riluzole on HSF1 was qualitatively different from that of MG132 and chloroquine, inhibitors of the proteasome and lysosome, respectively, and appeared to involve the chaperone-mediated autophagy pathway as RNAi-mediated knockdown of CMA negated its effect.	Riluzole	14-22	heat shock transcription factor 1	Homo sapiens	26-30
18682744-8	2008	CONCLUSION/SIGNIFICANCE: We show that riluzole increased the amount of HSF1 to amplify the HSR for cytoprotection.	Riluzole	38-46	heat shock transcription factor 1	Homo sapiens	71-75
18445055-9	2008	As riluzole is a protein kinase C (PKC) inhibitor, the PKC antagonist chelerythrine (2.5 microm) mimicked the effect of riluzole and prevented it.	Riluzole	3-11	protein kinase C, gamma	Rattus norvegicus	35-38
18445055-9	2008	As riluzole is a protein kinase C (PKC) inhibitor, the PKC antagonist chelerythrine (2.5 microm) mimicked the effect of riluzole and prevented it.	Riluzole	3-11	protein kinase C, gamma	Rattus norvegicus	55-58
18445055-9	2008	As riluzole is a protein kinase C (PKC) inhibitor, the PKC antagonist chelerythrine (2.5 microm) mimicked the effect of riluzole and prevented it.	Riluzole	120-128	protein kinase C, gamma	Rattus norvegicus	35-38
18445055-9	2008	As riluzole is a protein kinase C (PKC) inhibitor, the PKC antagonist chelerythrine (2.5 microm) mimicked the effect of riluzole and prevented it.	Riluzole	120-128	protein kinase C, gamma	Rattus norvegicus	55-58
18445055-10	2008	In summary, riluzole blocked the persistent sodium current fully, and the calcium one partly, plus it decreased glutamatergic transmission probably via inhibition of PKC that regulated presynaptic NMDA receptors having a facilitatory effect on glutamate release.	Riluzole	12-20	protein kinase C, gamma	Rattus norvegicus	166-169
17332361-8	2007	Treatment of GRM1-expressing human melanoma cells with a GRM1 antagonist (LY367385 or BAY36-7620) or a glutamate release inhibitor (riluzole) leads to a suppression of cell proliferation as well as a decrease in levels of extracellular glutamate.	Riluzole	132-140	glutamate metabotropic receptor 1	Homo sapiens	13-17
18098330-4	2008	From in vitro experiments, CYP1A2 seems to be mainly involved in riluzole clearance.	Riluzole	65-73	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	27-33
18098330-7	2008	It also aimed at relating glucuronidation of riluzole to differential UGT1A1*28 genotypes.	Riluzole	45-53	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	70-76
17852022-2	2007	Riluzole is assumed to be mainly metabolized by the liver cytochrome CYP1A2 and by the extra-hepatic cytochrome CYP1A1.	Riluzole	0-8	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	69-75
17852022-2	2007	Riluzole is assumed to be mainly metabolized by the liver cytochrome CYP1A2 and by the extra-hepatic cytochrome CYP1A1.	Riluzole	0-8	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	112-118
17852022-4	2007	The aim of this study was to determine whether the polymorphisms of the CYP1A2 and the CYP1A1 genes in ALS patients are associated with riluzole metabolic profiles.	Riluzole	136-144	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	72-78
17852022-4	2007	The aim of this study was to determine whether the polymorphisms of the CYP1A2 and the CYP1A1 genes in ALS patients are associated with riluzole metabolic profiles.	Riluzole	136-144	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	87-93
17852022-7	2007	Association of the genotypes of the SNPs spanning the CYP1A1 and CYP1A2 genes (including one SNP in the intergenic region) with mean riluzole peak and trough levels was studied using ANOVA and Tukey"s HSD.	Riluzole	133-141	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	54-60
17507170-4	2007	Both VPA and riluzole treatments reduced VGLUT1 immunoreactivity.	Riluzole	13-21	solute carrier family 17 member 7	Rattus norvegicus	41-47
18036519-0	2008	Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1.	Riluzole	0-8	solute carrier family 1 member 3	Rattus norvegicus	57-62
18036519-0	2008	Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1.	Riluzole	0-8	solute carrier family 1 member 2	Rattus norvegicus	64-68
18036519-0	2008	Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1.	Riluzole	0-8	solute carrier family 1 member 1	Rattus norvegicus	73-78
18075124-6	2007	In slice preparation, whole cell patch-clamp recordings made from developing motoneurons in SOD1(G85R) and double transgenic SOD1(G93A)/Hb9-eGFP mice showed that Riluzole, a blocker of persistent inward sodium conductance, altered the repetitive firing in a similar way for the 2 strains.	Riluzole	162-170	superoxide dismutase 1, soluble	Mus musculus	125-129
18075124-6	2007	In slice preparation, whole cell patch-clamp recordings made from developing motoneurons in SOD1(G85R) and double transgenic SOD1(G93A)/Hb9-eGFP mice showed that Riluzole, a blocker of persistent inward sodium conductance, altered the repetitive firing in a similar way for the 2 strains.	Riluzole	162-170	motor neuron and pancreas homeobox 1	Mus musculus	136-139
17852022-7	2007	Association of the genotypes of the SNPs spanning the CYP1A1 and CYP1A2 genes (including one SNP in the intergenic region) with mean riluzole peak and trough levels was studied using ANOVA and Tukey"s HSD.	Riluzole	133-141	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	65-71
17659475-4	2007	In addition, all members of the TREK familyare activated by neuroprotective agents, such as riluzole, polyunsaturated fatty acids and lysophospholipids, suggesting that these channels play an important role in neuroprotection.	Riluzole	92-100	potassium two pore domain channel subfamily K member 2	Homo sapiens	32-36
17460064-2	2007	We characterized I(Na(P)) in commissural interneurons (CINs) in the neonatal (postnatal days 0-3) mouse spinal cord; it is activated at subthreshold potentials, inactivates slowly, and can be blocked by low concentrations of riluzole.	Riluzole	225-233	catenin, beta like 1	Mus musculus	19-24
16936714-5	2007	We found that the agents with a predominantly antidepressant profile, namely lamotrigine and riluzole, significantly enhanced the surface expression of GluR1 and GluR2 in a time- and dose-dependent manner in cultured hippocampal neurons.	Riluzole	93-101	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	152-157
16936714-5	2007	We found that the agents with a predominantly antidepressant profile, namely lamotrigine and riluzole, significantly enhanced the surface expression of GluR1 and GluR2 in a time- and dose-dependent manner in cultured hippocampal neurons.	Riluzole	93-101	glutamate ionotropic receptor AMPA type subunit 2	Homo sapiens	162-167
16936714-7	2007	Concomitant with the GluR1 and GluR2 changes, the peak value of depolarized membrane potential evoked by AMPA was significantly higher in lamotrigine- and riluzole-treated neurons, supporting the surface receptor changes.	Riluzole	155-163	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	21-26
16936714-7	2007	Concomitant with the GluR1 and GluR2 changes, the peak value of depolarized membrane potential evoked by AMPA was significantly higher in lamotrigine- and riluzole-treated neurons, supporting the surface receptor changes.	Riluzole	155-163	glutamate ionotropic receptor AMPA type subunit 2	Homo sapiens	31-36
16936714-8	2007	Phosphorylation of GluR1 at the PKA (cAMP-dependent protein kinase) site (S845) was enhanced in both lamotrigine- and riluzole-treated hippocampal neurons, but reduced in valproate-treated neurons.	Riluzole	118-126	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	19-24
16936714-9	2007	In addition, lamotrigine and riluzole, as well as the traditional antidepressant imipramine, also increased GluR1 phosphorylation at GluR1 (S845) in the hippocampus after chronic in vivo treatment.	Riluzole	29-37	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	108-113
16936714-9	2007	In addition, lamotrigine and riluzole, as well as the traditional antidepressant imipramine, also increased GluR1 phosphorylation at GluR1 (S845) in the hippocampus after chronic in vivo treatment.	Riluzole	29-37	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	133-138
16815868-0	2006	Interaction of riluzole with the closed inactivated state of Kv4.3 channels.	Riluzole	15-23	potassium voltage-gated channel subfamily D member 3	Homo sapiens	61-66
16778007-4	2006	We speculated that Na(+) channel activity between APs, termed persistent Na(+) current (I(NaP)), is responsible for AP generation that and riluzole and phenytoin, which inhibit this current, would impair organ function.	Riluzole	139-147	sodium voltage-gated channel alpha subunit 8	Rattus norvegicus	19-32
16870839-8	2006	4) Voltage-clamp measurements show that riluzole (20 microM) and very low concentrations of TTX (50 nM) attenuate Na(P) currents in the neural membrane within a 1-min interval after bath application of the drug.	Riluzole	40-48	catenin, beta like 1	Mus musculus	114-119
16815868-1	2006	The effect of riluzole on Kv4.3 was examined using the whole-cell patch-clamp technique.	Riluzole	14-22	potassium voltage-gated channel subfamily D member 3	Homo sapiens	26-31
16815868-2	2006	Riluzole inhibited the peak amplitude of Kv4.3 in a reversible, concentration-dependent manner with an IC(50) of 115.6 microM.	Riluzole	0-8	potassium voltage-gated channel subfamily D member 3	Homo sapiens	41-46
16815868-7	2006	Riluzole shifted the voltage dependence of the steady-state inactivation of Kv4.3 in the hyperpolarizing direction in a concentration-dependent manner.	Riluzole	0-8	potassium voltage-gated channel subfamily D member 3	Homo sapiens	76-81
16815868-9	2006	The K(i) for riluzole for interacting with the inactivated state of Kv4.3 was estimated from the concentration-dependent shift in the steady-state inactivation curve and was determined to be 1.2 muM.	Riluzole	13-21	potassium voltage-gated channel subfamily D member 3	Homo sapiens	68-73
16815868-13	2006	Riluzole induced a significant use-dependent inhibition of Kv4.3.	Riluzole	0-8	potassium voltage-gated channel subfamily D member 3	Homo sapiens	59-64
16815868-14	2006	These results suggest that riluzole inhibits Kv4.3 by binding to the closed inactivated state of the channels and that the unbinding of riluzole occurs from the closed state during depolarization.	Riluzole	27-35	potassium voltage-gated channel subfamily D member 3	Homo sapiens	45-50
16524382-0	2006	Specific regulation of rat glial cell line-derived neurotrophic factor gene expression by riluzole in C6 glioma cells.	Riluzole	90-98	glial cell derived neurotrophic factor	Rattus norvegicus	27-70
16524382-10	2006	This study suggests that the regulation of GDNF gene transcription in glial cells could contribute to the pharmacological properties of riluzole and possibly other neuroprotective drugs.	Riluzole	136-144	glial cell derived neurotrophic factor	Rattus norvegicus	43-47
16524382-3	2006	We investigated the effects of the neuroprotective drug, riluzole, on the GDNF gene expression in glial cells.	Riluzole	57-65	glial cell derived neurotrophic factor	Rattus norvegicus	74-78
16524382-4	2006	Exposure of C6 glioma cells to riluzole (1 microM) significantly increased GDNF protein and mRNA levels.	Riluzole	31-39	glial cell derived neurotrophic factor	Rattus norvegicus	75-79
16524382-5	2006	Using luciferase reporter gene constructs encoding fragments of the 5" untranslated region of the rat GDNF gene, we demonstrated that riluzole mediates its effect at the transcription level.	Riluzole	134-142	glial cell derived neurotrophic factor	Rattus norvegicus	102-106
16524382-9	2006	Together, these results indicated that the induction of GDNF release by riluzole in the C6 glioma cells results from the activation of its corresponding gene promoter through a signalling pathway involving MEK activity.	Riluzole	72-80	glial cell derived neurotrophic factor	Rattus norvegicus	56-60
16311719-4	2006	Application of riluzole resulted in a large increase in I(sc), inhibited by apical application of either bupivicane or the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel blocker DPC.	Riluzole	15-23	CF transmembrane conductance regulator	Homo sapiens	123-174
16386734-8	2006	Our data confirm that riluzole has beneficial effects in wobbler mice, and suggest that these effects could be associated to the increased levels of the neurotrophic and neuroprotective factor BDNF.	Riluzole	22-30	brain derived neurotrophic factor	Mus musculus	193-197
16386734-7	2006	Immunostaining of cervical spinal cord sections shows that in riluzole-treated wobbler mice BDNF expression is significantly increased in motoneurons with no changes in the high-affinity receptor Trk-B.	Riluzole	62-70	brain derived neurotrophic factor	Mus musculus	92-96
16311719-4	2006	Application of riluzole resulted in a large increase in I(sc), inhibited by apical application of either bupivicane or the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel blocker DPC.	Riluzole	15-23	CF transmembrane conductance regulator	Homo sapiens	176-180
16303979-0	2005	Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo.	Riluzole	0-8	vascular endothelial growth factor A	Homo sapiens	18-22
16289892-1	2006	We investigated here the effects of alpha-linolenic acid and riluzole, both activators of the 2P-domain K+ channel family TREK/TRAAK, in a model of focal ischemia clinically relevant to stroke, not only assessing neuronal protection, but also long term survival.	Riluzole	61-69	potassium channel, subfamily K, member 4	Mus musculus	127-132
16360647-8	2006	In addition, riluzole appeared to produce nonspecific effects on c-Fos expression by itself, without specifically modifying c-Fos expression following naloxone-precipitated withdrawal in any region of the amygdala examined, suggesting that the amygdala may not serve as a specific site of action for riluzole.	Riluzole	13-21	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	65-70
16289892-8	2006	Alpha-linolenic acid- and riluzole treatment were associated with a reduction in cytopathological features of cell injury, including DNA fragmentation and Bax expression in the cortex and the caudate putamen.	Riluzole	26-34	BCL2-associated X protein	Mus musculus	155-158
16303979-1	2005	PURPOSE: The present study examined the effects of riluzole, a Food and Drug Administration-approved drug for amyotrophic lateral sclerosis, on VEGF-stimulated endothelial cell proliferation in culture, and on neovascularization in a rat model of retinopathy of prematurity (ROP).	Riluzole	51-59	vascular endothelial growth factor A	Rattus norvegicus	144-148
16303979-6	2005	RESULTS: Riluzole inhibited VEGF-stimulated PKC betaII activation and cell proliferation in bovine retinal endothelial cell and human umbilical vein endothelial cell cultures.	Riluzole	9-17	vascular endothelial growth factor A	Bos taurus	28-32
16303979-8	2005	CONCLUSIONS: The present results suggest that riluzole is a potent inhibitor of VEGF-induced endothelial cell proliferation both in vivo and in vitro.	Riluzole	46-54	vascular endothelial growth factor A	Homo sapiens	80-84
15613494-11	2005	We provide the first evidence that, in addition to secreting glutamate, retinal pigment epithelial cells express the vesicular glutamate transporter VGLUT1 and that regulated vesicular release of glutamate from these cells can be inhibited by riluzole.	Riluzole	243-251	solute carrier family 17 member 7	Homo sapiens	149-155
16224615-6	2005	Riluzole has been shown to reverse glutamate-mediated impairments in neuronal plasticity and to stimulate the synthesis of brain derived neurotrophic factor.	Riluzole	0-8	brain derived neurotrophic factor	Homo sapiens	123-156
15931073-4	2005	Tetrodotoxin completely blocked INa,S and single-channel current noise; 25 microM riluzole also suppressed INa,S and current noise by about 80% without a significant effect on mean single-channel current.	Riluzole	82-90	internexin neuronal intermediate filament protein, alpha	Rattus norvegicus	107-110
15917456-7	2005	Riluzole (3 microM), a putative I(NaP) antagonist, reduced both I(NaP) and I(NaT) and produced a hyperpolarizing shift in the voltage dependence of steady-state inactivation.	Riluzole	0-8	bromodomain containing 2	Homo sapiens	77-80
15583958-4	2005	DARPP-32 immunohistochemistry revealed a significant reduction of absolute striatal lesion volume in riluzole treated animals compared to lesioned but untreated animals (P<0.01).	Riluzole	101-109	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	0-8
15931073-1	2005	Slow depolarization induces a riluzole-sensitive persistent Na current (INa,P) in several types of neurons and a pharmacologically similar slowly inactivating Na current (INa,S) in rat suprachiasmatic nucleus neurons.	Riluzole	30-38	internexin neuronal intermediate filament protein, alpha	Rattus norvegicus	72-75
15473983-5	2004	Finally, treatment with riluzole or tetanus toxin attenuated the enhancement in both glutamate accumulation and oxygen-glucose deprivation-induced neuronal injury supporting the idea that increased synaptic release of glutamate underlies, at least in part, the potentiation of neuronal injury by RNOS after NOS-2 induction.	Riluzole	24-32	nitric oxide synthase 2, inducible	Mus musculus	307-312
15486012-3	2005	One particular member of the family, TREK-1 (also known as KCNK2), is activated by increasing temperature, membrane stretch and internal acidosis, but is also sensitive to the presence of certain polyunsaturated fatty acids (such as arachidonic acid), neuroprotectants (such as riluzole) and volatile and gaseous general anaesthetics (such as halothane and nitrous oxide).	Riluzole	278-286	potassium two pore domain channel subfamily K member 2	Homo sapiens	37-43
15486012-3	2005	One particular member of the family, TREK-1 (also known as KCNK2), is activated by increasing temperature, membrane stretch and internal acidosis, but is also sensitive to the presence of certain polyunsaturated fatty acids (such as arachidonic acid), neuroprotectants (such as riluzole) and volatile and gaseous general anaesthetics (such as halothane and nitrous oxide).	Riluzole	278-286	potassium two pore domain channel subfamily K member 2	Homo sapiens	59-64
15752377-0	2005	Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis.	Riluzole	40-48	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	20-26
15752377-3	2005	Riluzole is assumed to be mainly metabolized by the cytochrome P450 enzyme 1A2 (CYP1A2).	Riluzole	0-8	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	52-78
15752377-3	2005	Riluzole is assumed to be mainly metabolized by the cytochrome P450 enzyme 1A2 (CYP1A2).	Riluzole	0-8	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	80-86
15752377-4	2005	The aim of the study was to investigate the relationship between CYP1A2 activity and riluzole clearance with a view to optimize drug treatment.	Riluzole	85-93	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	65-71
15752377-8	2005	RESULTS: Riluzole clearance and the serum paraxanthine : caffeine (P/C) ratio showed a positive correlation (r = 0.693; P = 0.0002).	Riluzole	9-17	pyruvate carboxylase	Homo sapiens	67-70
15752377-9	2005	Linear regression analysis identified the P/C ratio (beta: 1.16) and height (beta: 0.027) as independent predictors of riluzole clearance (adjusted r2 = 0.369).	Riluzole	119-127	pyruvate carboxylase	Homo sapiens	42-45
15752377-10	2005	CONCLUSIONS: The P/C ratio, used as measure of CYP1A2 activity, significantly correlated with the riluzole clearance, although only 37% of the observed variability could be explained.	Riluzole	98-106	pyruvate carboxylase	Homo sapiens	17-20
15752377-10	2005	CONCLUSIONS: The P/C ratio, used as measure of CYP1A2 activity, significantly correlated with the riluzole clearance, although only 37% of the observed variability could be explained.	Riluzole	98-106	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	47-53
16909020-6	2005	Moreover, the therapeutic efficacy of riluzole, the only drug proven to slow disease progression in ALS, is most likely related to its anti-excitotoxic properties.	Riluzole	38-46	superoxide dismutase 1	Homo sapiens	100-103
15964489-0	2005	Inhibition of the cloned delayed rectifier K+ channels, Kv1.5 and Kv3.1, by riluzole.	Riluzole	76-84	potassium voltage-gated channel subfamily A member 5	Homo sapiens	56-61
15964489-0	2005	Inhibition of the cloned delayed rectifier K+ channels, Kv1.5 and Kv3.1, by riluzole.	Riluzole	76-84	potassium voltage-gated channel subfamily C member 1	Homo sapiens	66-71
15964489-1	2005	The action of riluzole, a neuroprotective drug, on cloned delayed rectifier K+ channels (Kv1.5 and Kv3.1) was examined using the whole-cell patch-clamp technique.	Riluzole	14-22	potassium voltage-gated channel subfamily A member 5	Homo sapiens	89-94
15964489-1	2005	The action of riluzole, a neuroprotective drug, on cloned delayed rectifier K+ channels (Kv1.5 and Kv3.1) was examined using the whole-cell patch-clamp technique.	Riluzole	14-22	potassium voltage-gated channel subfamily C member 1	Homo sapiens	99-104
15964489-2	2005	Riluzole reversibly inhibited Kv1.5 currents in a concentration-dependent manner with an IC50 of 39.69+/-2.37 microM.	Riluzole	0-8	potassium voltage-gated channel subfamily A member 5	Homo sapiens	30-35
15964489-5	2005	Riluzole shifted the steady-state inactivation curves of Kv1.5 in a hyperpolarizing direction in a concentration-dependent manner.	Riluzole	0-8	potassium voltage-gated channel subfamily A member 5	Homo sapiens	57-62
15964489-7	2005	Riluzole exhibited a use-independent inhibition of Kv1.5.	Riluzole	0-8	potassium voltage-gated channel subfamily A member 5	Homo sapiens	51-56
15964489-9	2005	Riluzole caused a concentration-dependent inhibition of Kv3.1 currents with an IC50 of 120.98+/-9.74 microM and also shifted the steady-state inactivation curve of Kv3.1 in the hyperpolarizing direction.	Riluzole	0-8	potassium voltage-gated channel subfamily C member 1	Homo sapiens	56-61
15964489-9	2005	Riluzole caused a concentration-dependent inhibition of Kv3.1 currents with an IC50 of 120.98+/-9.74 microM and also shifted the steady-state inactivation curve of Kv3.1 in the hyperpolarizing direction.	Riluzole	0-8	potassium voltage-gated channel subfamily C member 1	Homo sapiens	164-169
15964489-10	2005	Thus, riluzole inhibits both Kv1.5 and Kv3.1 currents in a concentration-dependent manner and interacts directly with Kv1.5 by preferentially binding to the inactivated and to the closed states of the channel.	Riluzole	6-14	potassium voltage-gated channel subfamily A member 5	Homo sapiens	29-34
15964489-10	2005	Thus, riluzole inhibits both Kv1.5 and Kv3.1 currents in a concentration-dependent manner and interacts directly with Kv1.5 by preferentially binding to the inactivated and to the closed states of the channel.	Riluzole	6-14	potassium voltage-gated channel subfamily C member 1	Homo sapiens	39-44
15964489-10	2005	Thus, riluzole inhibits both Kv1.5 and Kv3.1 currents in a concentration-dependent manner and interacts directly with Kv1.5 by preferentially binding to the inactivated and to the closed states of the channel.	Riluzole	6-14	potassium voltage-gated channel subfamily A member 5	Homo sapiens	118-123
15140906-9	2004	Riluzole (500 microM), selective for TREK-1 and -2 channels, enhanced acid taste responses.	Riluzole	0-8	potassium channel, subfamily K, member 2	Mus musculus	37-50
15062101-6	2004	Inactivation of dEAAT1 by RNA interference led to characteristic behavior deficits that were significantly rescued by expression of the human glutamate transporter hEAAT2 or the administration in food of riluzole, an anti-excitotoxic agent used in the clinic for human ALS patients.	Riluzole	204-212	Excitatory amino acid transporter 1	Drosophila melanogaster	16-22
15063340-6	2004	The method is currently used to support pharmacological studies of the activity of riluzole when given in combination with other potential neuroprotective agents in an animal model of familiar amyotrophic lateral sclerosis (SOD1-G93A transgenic mice).	Riluzole	83-91	superoxide dismutase 1, soluble	Mus musculus	224-228
12154010-0	2002	Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus.	Riluzole	0-8	brain-derived neurotrophic factor	Rattus norvegicus	32-65
12372901-6	2002	A low concentration (6 micromol/l) of riluzole selectively potentiated the bradykinin (but not ATP and histamine)-induced increase in [Ca(2+)](i).	Riluzole	38-46	kininogen 1	Homo sapiens	75-85
12163105-2	2002	We used patch clamp to study the actions of the neuroprotective drug riluzole on recombinant SK2 channels expressed in HEK293 cells and native SK channels underlying the afterhyperpolarization current (I(AHP)) in cultured hippocampal neurons.	Riluzole	69-77	sphingosine kinase 2	Homo sapiens	93-96
12163105-3	2002	External riluzole activated whole-cell SK2 channel currents in HEK293 cells dialyzed with a Ca(2+)-free intracellular solution.	Riluzole	9-17	sphingosine kinase 2	Homo sapiens	39-42
14556941-2	2003	Therefore, we examined whether riluzole, an inhibitor of glutamate transmission, affects the pathogenesis and clinical features of MS-like disease in myelin oligodendrocyte glycoprotein (MOG)-induced EAE in mice.	Riluzole	31-39	myelin oligodendrocyte glycoprotein	Mus musculus	187-190
14556941-8	2003	In conclusion, our study demonstrates, for the first time, that riluzole can reduce inflammation, demyelination and axonal damage in the CNS and attenuate the clinical severity of MOG-induced EAE.	Riluzole	64-72	myelin oligodendrocyte glycoprotein	Mus musculus	180-183
12629173-8	2003	Altered expression of astroglial glutamate transporters accompanied by reduced capacity for spinal cord clearance of extracellular glutamate in the G93A SOD1 transgenic rat may account for a dampened effect of riluzole to enhance glutamate uptake at end-stage disease.	Riluzole	210-218	superoxide dismutase 1	Rattus norvegicus	153-157
12154010-4	2002	Among ion channel modulators tested, riluzole, a neuroprotective agent with anticonvulsant properties that is approved for treatment of amyotrophic lateral sclerosis, was highly effective as a single dose by an intraperitoneal injection, causing a rise in BDNF localized in dentate granule neurons, the hilus, and the stratum radiatum of the CA3 region.	Riluzole	37-45	brain-derived neurotrophic factor	Rattus norvegicus	256-260
12154010-7	2002	Intraventricular administration of BDNF-specific antibodies blocked such riluzole effects, suggesting that BDNF increase is necessary for the promotion of precursor proliferation.	Riluzole	73-81	brain-derived neurotrophic factor	Rattus norvegicus	35-39
12154010-7	2002	Intraventricular administration of BDNF-specific antibodies blocked such riluzole effects, suggesting that BDNF increase is necessary for the promotion of precursor proliferation.	Riluzole	73-81	brain-derived neurotrophic factor	Rattus norvegicus	107-111
11578843-7	2001	Our immunohistochemical study with TH and MAP 2 staining showed that riluzole can protect against MPTP-induced neuronal damage in the substantia nigra.	Riluzole	69-77	microtubule-associated protein 2	Mus musculus	42-47
11578843-8	2001	Furthermore, riluzole markedly increased the striatal GFAP-positive astrocytes 3 days after MPTP treatments.	Riluzole	13-21	glial fibrillary acidic protein	Mus musculus	54-58
11053038-10	2000	The recent demonstration that TASK-1 and TREK-1 channels are activated by inhalational general anesthetics, and that TRAAK is activated by the neuroprotective agent riluzole, indicates that this novel class of K(+) channels is an interesting target for new therapeutic developments.	Riluzole	165-173	potassium two pore domain channel subfamily K member 4	Homo sapiens	117-122
11585581-0	2001	Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes.	Riluzole	0-8	nerve growth factor	Mus musculus	20-39
11585581-0	2001	Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes.	Riluzole	0-8	brain derived neurotrophic factor	Mus musculus	41-74
11585581-0	2001	Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes.	Riluzole	0-8	glial cell line derived neurotrophic factor	Mus musculus	79-122
11585581-4	2001	Treatment with riluzole at 100 microg/ml (426 microM) for 24 h increased the contents of NGF, BDNF, and GDNF in the culture medium 109-fold, 2.0-fold and 3.1-fold over the control, respectively.	Riluzole	15-23	nerve growth factor	Mus musculus	89-92
11585581-4	2001	Treatment with riluzole at 100 microg/ml (426 microM) for 24 h increased the contents of NGF, BDNF, and GDNF in the culture medium 109-fold, 2.0-fold and 3.1-fold over the control, respectively.	Riluzole	15-23	brain derived neurotrophic factor	Mus musculus	94-98
11585581-4	2001	Treatment with riluzole at 100 microg/ml (426 microM) for 24 h increased the contents of NGF, BDNF, and GDNF in the culture medium 109-fold, 2.0-fold and 3.1-fold over the control, respectively.	Riluzole	15-23	glial cell line derived neurotrophic factor	Mus musculus	104-108
11585581-6	2001	These results indicate that riluzole stimulates synthesis of NGF, BDNF and GDNF in cultured astrocytes.	Riluzole	28-36	nerve growth factor	Mus musculus	61-64
11585581-6	2001	These results indicate that riluzole stimulates synthesis of NGF, BDNF and GDNF in cultured astrocytes.	Riluzole	28-36	brain derived neurotrophic factor	Mus musculus	66-70
11585581-6	2001	These results indicate that riluzole stimulates synthesis of NGF, BDNF and GDNF in cultured astrocytes.	Riluzole	28-36	glial cell line derived neurotrophic factor	Mus musculus	75-79
11378158-6	2001	Riluzole, a potent neuroprotective drug with anti-ischemic, anticonvulsant and sedative effects currently used in the treatment of amyotrophic lateral sclerosis, activates SK3 channels at concentrations of 3 microM and above.	Riluzole	0-8	potassium calcium-activated channel subfamily N member 3	Homo sapiens	172-175
11465930-4	2001	In addition, the first systematic review in the field of ALS/MND from the Cochrane collaboration concerns riluzole treatment and this meta-analysis is also described.	Riluzole	106-114	superoxide dismutase 1	Homo sapiens	57-60
11036167-1	2000	We hypothesized that anesthetic dose of riluzole, an inhibitor of glutamate neurotransmission, may affect the activity and/or expression of neuronal NOS (nNOS).	Riluzole	40-48	nitric oxide synthase 1	Rattus norvegicus	140-152
11036167-1	2000	We hypothesized that anesthetic dose of riluzole, an inhibitor of glutamate neurotransmission, may affect the activity and/or expression of neuronal NOS (nNOS).	Riluzole	40-48	nitric oxide synthase 1	Rattus norvegicus	154-158
11036167-2	2000	Riluzole, N(G)-nitro-L-arginine-methyl ester (L-NAME) and 7-nitro indazole (7-NI) produced a concentration-related inhibition of nNOS activity in vitro.	Riluzole	0-8	nitric oxide synthase 1	Rattus norvegicus	129-133
11036167-3	2000	Riluzole competed with 7-NI for inhibition of nNOS activity, but had no effect on nNOS or endothelial NOS (eNOS) protein expression.	Riluzole	0-8	nitric oxide synthase 1	Rattus norvegicus	46-50
11036167-4	2000	Also, nNOS activity was significantly decreased in riluzole-anesthetized rats (40 mg kg(-1) i.p., -32+/-6% from controls, P&lt;0.05).	Riluzole	51-59	nitric oxide synthase 1	Rattus norvegicus	6-10
11036167-5	2000	Therefore, blockade of nNOS activity may be involved in the anesthetic effects of riluzole in vivo.	Riluzole	82-90	nitric oxide synthase 1	Rattus norvegicus	23-27
10540024-11	1999	Co-administration of IGF-I (1.0 mg/kg) and riluzole (5.0 mg/kg) was more effective than either agent alone and there was a statistically significant difference between co-administration and IGF-I alone.	Riluzole	43-51	insulin-like growth factor 1	Rattus norvegicus	190-195
10880510-12	2000	As with TREK1, TREK2 is activated by the volatile general anesthetics chloroform, halothane, and isoflurane and by the neuroprotective agent riluzole.	Riluzole	141-149	potassium two pore domain channel subfamily K member 2	Homo sapiens	8-13
10880510-12	2000	As with TREK1, TREK2 is activated by the volatile general anesthetics chloroform, halothane, and isoflurane and by the neuroprotective agent riluzole.	Riluzole	141-149	potassium two pore domain channel subfamily K member 10	Homo sapiens	15-20
10779373-0	2000	The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK.	Riluzole	26-34	potassium two pore domain channel subfamily K member 2	Homo sapiens	76-82
10779373-0	2000	The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK.	Riluzole	26-34	potassium two pore domain channel subfamily K member 4	Homo sapiens	87-92
10779373-3	2000	This article reports that riluzole is an activator of TREK-1 and TRAAK, two important members of a new structural family of mammalian background K(+) channels with four transmembrane domains and two pore regions.	Riluzole	26-34	potassium two pore domain channel subfamily K member 2	Homo sapiens	54-60
10779373-3	2000	This article reports that riluzole is an activator of TREK-1 and TRAAK, two important members of a new structural family of mammalian background K(+) channels with four transmembrane domains and two pore regions.	Riluzole	26-34	potassium two pore domain channel subfamily K member 4	Homo sapiens	65-70
10779373-4	2000	Whereas riluzole activation of TRAAK is sustained, activation of TREK-1 is transient and is followed by an inhibition.	Riluzole	8-16	potassium two pore domain channel subfamily K member 4	Homo sapiens	31-36
10779373-5	2000	The inhibitory process is attributable to an increase of the intracellular cAMP concentration by riluzole that produces a protein kinase A-dependent inhibition of TREK-1.	Riluzole	97-105	potassium two pore domain channel subfamily K member 2	Homo sapiens	163-169
10779373-6	2000	Mutants of TREK-1 lacking the Ser residue where the kinase A phosphorylation takes place are activated in a sustained manner by riluzole.	Riluzole	128-136	potassium two pore domain channel subfamily K member 2	Homo sapiens	11-17
10779373-7	2000	TRAAK is permanently activated by riluzole because, unlike TREK-1, it lacks the negative regulation by cAMP.	Riluzole	34-42	potassium two pore domain channel subfamily K member 4	Homo sapiens	0-5
10779373-7	2000	TRAAK is permanently activated by riluzole because, unlike TREK-1, it lacks the negative regulation by cAMP.	Riluzole	34-42	potassium two pore domain channel subfamily K member 2	Homo sapiens	59-65
11018250-12	2000	Comparison between patients treated or not with riluzole did not display any modification of the plasma TBARS concentration, but we observed a slight decrease of erythrocyte SOD activity in treated patients (treated=705+/-113 U/g Hb; not treated=725+/-118 U/g Hb), suggesting a possible activity of riluzole on the oxygenated free radical production.	Riluzole	48-56	superoxide dismutase 1	Homo sapiens	174-177
10876221-13	2000	Moreover, MAP-2 immunoreactivity was completely lost in control rabbits, whereas it was preserved, either completely or partially, in rabbits treated with riluzole or magnesium.	Riluzole	155-163	microtubule-associated protein 2	Oryctolagus cuniculus	10-15
10572379-7	1999	Under inside-out patch recording mode, riluzole (10 mumol/L) applied intracellularly can increase the opening probability of large-conductance Ca(2+)-activated K+(BKCa) channels, but did not affect their single-channel conductance.	Riluzole	39-47	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	163-167
10572379-8	1999	The riluzole-induced change in the kinetic behavior of BKCa channels is due to an increase in mean open time and a decrease in mean closed time.	Riluzole	4-12	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	55-59
10572379-10	1999	Riluzole-stimulated activity of BKCa is independent on internal Ca2+.	Riluzole	0-8	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	32-36
10572379-13	1999	In rat pheochromocytoma PC12 cells, riluzole also increased the activity of BKCa channels without altering their channel conductance.	Riluzole	36-44	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	76-80
10572379-14	1999	CONCLUSION: This study shows that riluzole can stimulate the activity of BKCa channel in neuroendocrine cells.	Riluzole	34-42	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	73-77
10204090-6	1999	Finally, results obtained from the experiments performed with PAF in the presence of riluzole, to inhibit the glutamate release, demonstrated that glutamate release is a stage in the PAF-induced increase of cyclic GMP levels in hippocampus.	Riluzole	85-93	5'-nucleotidase, cytosolic II	Homo sapiens	214-217
10425092-5	1999	Among the second series of variously substituted benzothiazolines, compounds as active as riluzole or up to 3 times more potent were identified in two series: benzothiazolines bearing a beta-dialkylaminoethyl moiety and compounds with an alkylthioalkyl chain and their corresponding sulfoxides and sulfones.	Riluzole	90-98	amyloid beta precursor protein	Rattus norvegicus	184-190
9930745-5	1999	Consistent with its antioxidative effects, riluzole reduced Fe3+-induced lipid peroxidation, and inhibited cytosolic phospholipase A2.	Riluzole	43-51	phospholipase A2 group IVA	Homo sapiens	107-133
10204090-6	1999	Finally, results obtained from the experiments performed with PAF in the presence of riluzole, to inhibit the glutamate release, demonstrated that glutamate release is a stage in the PAF-induced increase of cyclic GMP levels in hippocampus.	Riluzole	85-93	PCNA clamp associated factor	Homo sapiens	62-65
10204090-6	1999	Finally, results obtained from the experiments performed with PAF in the presence of riluzole, to inhibit the glutamate release, demonstrated that glutamate release is a stage in the PAF-induced increase of cyclic GMP levels in hippocampus.	Riluzole	85-93	PCNA clamp associated factor	Homo sapiens	183-186
9930745-8	1999	The present study demonstrates that riluzole has direct antioxidative actions, perhaps in part by inhibiting phospholipase A2.	Riluzole	36-44	phospholipase A2 group IB	Homo sapiens	109-125
8891467-9	1996	Elevated alanine aminotransferase levels were observed in 10.6 versus 3.8% of patients treated with riluzole 100 mg/day versus placebo, leading to treatment withdrawal in 3.8 versus 2.1% of patients.	Riluzole	100-108	glutamic--pyruvic transaminase	Homo sapiens	9-33
9628867-9	1998	TRAAK channels are stimulated by the neuroprotective drug riluzole.	Riluzole	58-66	potassium two pore domain channel subfamily K member 4	Homo sapiens	0-5
9326288-7	1997	Finally, treatment of animals with riluzole, an inhibitor of glutamate release, before surgery reduced significantly the loss of MAP2 levels observed at 24 h after injury.	Riluzole	35-43	microtubule associated protein 2	Homo sapiens	129-133
8959996-0	1996	A confirmatory dose-ranging study of riluzole in ALS.	Riluzole	37-45	superoxide dismutase 1	Homo sapiens	49-52
8959996-3	1996	The anti-excitotoxic drug riluzole (100 mg/day) has been shown to decrease mortality and muscular deterioration in ALS patients.	Riluzole	26-34	superoxide dismutase 1	Homo sapiens	115-118
8959996-12	1996	This study confirms the therapeutic effect of riluzole in a large representative ALS sample, over an 18-month period.	Riluzole	46-54	superoxide dismutase 1	Homo sapiens	81-84
8959996-13	1996	Riluzole is well tolerated and decreases the risk of death or tracheostomy in ALS patients.	Riluzole	0-8	superoxide dismutase 1	Homo sapiens	78-81
9316860-1	1997	Cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) isoenzymes involved in riluzole oxidation and glucuronidation were characterized in (1) kinetic studies with human hepatic microsomes and isoenzyme-selective probes and (2) metabolic studies with genetically expressed human CYP isoenzymes from transfected B-lymphoblastoid and yeast cells.	Riluzole	99-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
9316860-1	1997	Cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) isoenzymes involved in riluzole oxidation and glucuronidation were characterized in (1) kinetic studies with human hepatic microsomes and isoenzyme-selective probes and (2) metabolic studies with genetically expressed human CYP isoenzymes from transfected B-lymphoblastoid and yeast cells.	Riluzole	99-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
9316860-1	1997	Cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) isoenzymes involved in riluzole oxidation and glucuronidation were characterized in (1) kinetic studies with human hepatic microsomes and isoenzyme-selective probes and (2) metabolic studies with genetically expressed human CYP isoenzymes from transfected B-lymphoblastoid and yeast cells.	Riluzole	99-107	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	26-69
9316860-1	1997	Cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) isoenzymes involved in riluzole oxidation and glucuronidation were characterized in (1) kinetic studies with human hepatic microsomes and isoenzyme-selective probes and (2) metabolic studies with genetically expressed human CYP isoenzymes from transfected B-lymphoblastoid and yeast cells.	Riluzole	99-107	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	71-74
9316860-1	1997	Cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) isoenzymes involved in riluzole oxidation and glucuronidation were characterized in (1) kinetic studies with human hepatic microsomes and isoenzyme-selective probes and (2) metabolic studies with genetically expressed human CYP isoenzymes from transfected B-lymphoblastoid and yeast cells.	Riluzole	99-107	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	300-303
9316860-5	1997	CYP1A2 was the only genetically expressed human P450 isoenzyme in B-lymphoblastoid microsomes to metabolize riluzole.	Riluzole	108-116	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	0-6
9316860-6	1997	Riluzole glucuronidation was inhibited most potently by propofol, a substrate for the human hepatic UGT HP4 (UGT1.8/9) isoenzyme.	Riluzole	0-8	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	100-103
9316860-6	1997	Riluzole glucuronidation was inhibited most potently by propofol, a substrate for the human hepatic UGT HP4 (UGT1.8/9) isoenzyme.	Riluzole	0-8	defensin alpha 4	Homo sapiens	104-107
9316860-6	1997	Riluzole glucuronidation was inhibited most potently by propofol, a substrate for the human hepatic UGT HP4 (UGT1.8/9) isoenzyme.	Riluzole	0-8	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	109-115
9316860-8	1997	Riluzole (1 and 10 microM) produced a weak, concentration-dependent inhibition of CYP1A2 activity and showed competitive inhibition of methoxyresorufin O-demethylase.	Riluzole	0-8	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	82-88
9316860-9	1997	Thus, riluzole is predominantly metabolized by CYP1A2 in human hepatic microsomes to N-hydroxyriluzole; extrahepatic CYP1A1 can also be responsible for the formation of several other metabolites.	Riluzole	6-14	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	47-53
9316860-9	1997	Thus, riluzole is predominantly metabolized by CYP1A2 in human hepatic microsomes to N-hydroxyriluzole; extrahepatic CYP1A1 can also be responsible for the formation of several other metabolites.	Riluzole	6-14	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	117-123
8112408-0	1993	The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1.	Riluzole	26-34	carbonic anhydrase 1	Homo sapiens	111-114
7853017-0	1994	Prevention of HIV coat protein (gp120) toxicity in cortical cell cultures by riluzole.	Riluzole	77-85	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	32-37
7853017-5	1994	We have analysed the effects of riluzole, a compound reducing the excitatory amino acid release on gp120-induced neurotoxicity in primary neuronal cultures.	Riluzole	32-40	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	99-104
7853017-6	1994	Riluzole, which blocks the release of glutamate and aspartate from nerve terminals, prevents (10(-7) M) the neuronal degeneration produced by 20 pM of gp120 in cortical cell cultures.	Riluzole	0-8	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	151-156
8112408-2	1993	This study demonstrated that 10-30 microM riluzole reduces the K(+)-evoked release of glutamate and aspartate from slices of hippocampal area CA1.	Riluzole	42-50	carbonic anhydrase 1	Homo sapiens	142-145
8474857-3	1993	The concentrations of riluzole inducing half maximum reduction of slow, fast 1 and fast 2 K conductances were 413 microM, 24 microM and 21 microM respectively.	Riluzole	22-30	forkhead box H1	Homo sapiens	72-78
8474857-3	1993	The concentrations of riluzole inducing half maximum reduction of slow, fast 1 and fast 2 K conductances were 413 microM, 24 microM and 21 microM respectively.	Riluzole	22-30	forkhead box H1	Homo sapiens	83-89
34616479-3	2021	Therefore, this study investigated whether combined treatment with Bojungikgi-tang and riluzole could act synergistically in transactive response DNA-binding protein 43 (TDP-43) stress granule cells.	Riluzole	87-95	TAR DNA binding protein	Homo sapiens	170-176
33767237-0	2021	In silico studies reveal structural deviations of mutant profilin-1 and interaction with riluzole and edaravone in amyotrophic lateral sclerosis.	Riluzole	89-97	profilin 1	Homo sapiens	57-67
33767237-7	2021	The potential effect of riluzole and edaravone two FDA approved drugs for ALS, impacting the structural deviations and stabilization of the mutant PFN-1 is evaluated using in silico tools.	Riluzole	24-32	profilin 1	Homo sapiens	147-152
34802899-12	2021	We found that treatment with riluzole increased median survival in Npc1-/- by 12%.	Riluzole	29-37	NPC intracellular cholesterol transporter 1	Mus musculus	67-71
34697383-3	2021	In the present study we investigated the role of YAP in apoptosis in osteosarcoma, we hypothesized that YAP may be activated by Riluzole to induce apoptosis in osteosarcoma.	Riluzole	128-136	Yes1 associated transcriptional regulator	Homo sapiens	104-107
34697383-5	2021	Riluzole caused translocation of YAP from the cytoplasm to the nucleus, indicating YAP"s role in apoptosis.	Riluzole	0-8	Yes1 associated transcriptional regulator	Homo sapiens	33-36
34697383-5	2021	Riluzole caused translocation of YAP from the cytoplasm to the nucleus, indicating YAP"s role in apoptosis.	Riluzole	0-8	Yes1 associated transcriptional regulator	Homo sapiens	83-86
34697383-6	2021	Both Riluzole-induced phosphorylation of YAP at tyrosine 357 and Riluzole-induced apoptosis were blocked by inhibitors of c-Abl kinase.	Riluzole	5-13	Yes1 associated transcriptional regulator	Homo sapiens	41-44
34697383-7	2021	In addition, knockdown of c-Abl kinase prevented Riluzole-induced apoptosis in LM7 cells.	Riluzole	49-57	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	26-31
34697383-8	2021	We further demonstrated that Riluzole promoted interaction between YAP and p73, while c-Abl kinase inhibitors abolished the interaction.	Riluzole	29-37	Yes1 associated transcriptional regulator	Homo sapiens	67-70
34697383-8	2021	We further demonstrated that Riluzole promoted interaction between YAP and p73, while c-Abl kinase inhibitors abolished the interaction.	Riluzole	29-37	tumor protein p73	Homo sapiens	75-78
34697383-9	2021	Subsequently, we demonstrated that Riluzole enhanced activity of the Bax promoter in a luciferase reporter assay and enhanced YAP/p73 binding on endogenous Bax promoter in a ChIP assay.	Riluzole	35-43	BCL2 associated X, apoptosis regulator	Homo sapiens	69-72
34697383-9	2021	Subsequently, we demonstrated that Riluzole enhanced activity of the Bax promoter in a luciferase reporter assay and enhanced YAP/p73 binding on endogenous Bax promoter in a ChIP assay.	Riluzole	35-43	Yes1 associated transcriptional regulator	Homo sapiens	126-129
34697383-9	2021	Subsequently, we demonstrated that Riluzole enhanced activity of the Bax promoter in a luciferase reporter assay and enhanced YAP/p73 binding on endogenous Bax promoter in a ChIP assay.	Riluzole	35-43	tumor protein p73	Homo sapiens	130-133
34697383-9	2021	Subsequently, we demonstrated that Riluzole enhanced activity of the Bax promoter in a luciferase reporter assay and enhanced YAP/p73 binding on endogenous Bax promoter in a ChIP assay.	Riluzole	35-43	BCL2 associated X, apoptosis regulator	Homo sapiens	156-159
34697383-10	2021	Our data supports a novel mechanism in which Riluzole activates c-Abl kinase to regulate pro-apoptotic activity of YAP in osteosarcoma.	Riluzole	45-53	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	64-69
34697383-10	2021	Our data supports a novel mechanism in which Riluzole activates c-Abl kinase to regulate pro-apoptotic activity of YAP in osteosarcoma.	Riluzole	45-53	Yes1 associated transcriptional regulator	Homo sapiens	115-118
35052677-7	2022	Combined administration of BJIGT and RZ did not alter mRNA expression levels of drug-metabolism-related isozymes (CYP1A2 and CYP3A4) but significantly decreased the activity of liver-function-related enzymes (AST, ALT, ALP, and LDH).	Riluzole	37-39	transmembrane protease, serine 11d	Mus musculus	209-212
35462095-6	2022	The normal saline-treated AbetaPP-PS1 mice exhibited a decrease in learning and memory that were restored to the control level following riluzole treatment.	Riluzole	137-145	presenilin 1	Mus musculus	34-37
35326229-0	2022	Combined Treatment with Bojungikgi-Tang and Riluzole Regulates Muscle Metabolism and Dysfunction in the hSOD1G93A Mouse Model.	Riluzole	44-52	superoxide dismutase 1	Homo sapiens	104-109
35326229-10	2022	Moreover, after BJIGT/RZ treatment, the number of Nissl-stained motoneurons and choline acetyl transferase-positive neurons in the spinal cord significantly increased via the regulation of proinflammatory cytokines.	Riluzole	22-24	choline acetyltransferase	Mus musculus	80-106
35063116-15	2022	SARA score showed a median increase (ie, worsening) of 0 5 points (IQR -1 5 to 1 5) in the riluzole group versus 0 3 points (-1 0 to 2 5) in the placebo group (p=0 70).	Riluzole	91-99	secretion associated Ras related GTPase 1A	Homo sapiens	0-4
35432830-0	2022	Effect of Riluzole on the Expression of HCN2 in Dorsal Root Ganglion Neurons of Diabetic Neuropathic Pain Rats.	Riluzole	10-18	hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2	Rattus norvegicus	40-44
35432830-8	2022	Our results indicate riluzole as the alleviator to STZ-induced DNP with involvement of downregulated HCN2 in lumbar DRG by continual systemic administration in rats.	Riluzole	21-29	hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2	Rattus norvegicus	101-105
34988900-4	2022	Riluzole applied in a single dose immediately post-SCI decreased the mRNA level of interleukin-1beta at 6 h, reduced the destruction of neurons, and reduced the activation of microglia/macrophage M1 expression at day 1 post-SCI.	Riluzole	0-8	interleukin 1 beta	Rattus norvegicus	83-100
34988900-5	2022	Additionally, riluzole-treated rats showed higher expressions of interleukin-33 and its receptor ST2 in microglia/macrophages of the spinal cord than vehicle-treated rats, suggesting that this signaling pathway might be involved in microglia/macrophage-mediated inflammation.	Riluzole	14-22	interleukin 33	Rattus norvegicus	65-79
34988900-5	2022	Additionally, riluzole-treated rats showed higher expressions of interleukin-33 and its receptor ST2 in microglia/macrophages of the spinal cord than vehicle-treated rats, suggesting that this signaling pathway might be involved in microglia/macrophage-mediated inflammation.	Riluzole	14-22	interleukin 1 receptor-like 1	Rattus norvegicus	97-100
34988900-7	2022	In addition, riluzole-treated rats exhibited higher expression of GAP43 protein and shorter N1 peak latency and larger N1-P1 amplitude in motor-evoked potentials, compared to vehicle-treated rats.	Riluzole	13-21	growth associated protein 43	Rattus norvegicus	66-71
35330860-5	2022	Hence, we tested the impact of riluzole, which potentiates glutamate clearance by astrocytic glutamate transporters, on principal neurons and astrocytes in the basal amygdala (BA) and hippocampal area CA1.	Riluzole	31-39	carbonic anhydrase 1	Rattus norvegicus	201-204
35330860-11	2022	Further, chronic stress and riluzole alone decreased the neuropil volume occupied by astrocytes in both the BA and CA1 area.	Riluzole	28-36	carbonic anhydrase 1	Rattus norvegicus	115-118
35323793-8	2022	Animal behavioral tests, as well as pathological and biochemical assays, were performed to clarify the role of EAAT3 function in POCD and evaluate the effect of activating the EAAT3 function by riluzole.	Riluzole	194-202	solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1	Mus musculus	176-181
35323793-11	2022	Moreover, riluzole pretreatment significantly increased the expression of hippocampal EAAT3 membrane protein and also ameliorated LPS-induced cognitive impairment in elderly male mice.	Riluzole	10-18	solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1	Mus musculus	86-91
35052677-7	2022	Combined administration of BJIGT and RZ did not alter mRNA expression levels of drug-metabolism-related isozymes (CYP1A2 and CYP3A4) but significantly decreased the activity of liver-function-related enzymes (AST, ALT, ALP, and LDH).	Riluzole	37-39	glutamic pyruvic transaminase, soluble	Mus musculus	214-217
35052677-7	2022	Combined administration of BJIGT and RZ did not alter mRNA expression levels of drug-metabolism-related isozymes (CYP1A2 and CYP3A4) but significantly decreased the activity of liver-function-related enzymes (AST, ALT, ALP, and LDH).	Riluzole	37-39	alopecia, recessive	Mus musculus	219-222
35052677-11	2022	Co-administration of BJIGT and RZ did not cause liver damage or toxicity but rather restored liver function in hSOD1G93A mice.	Riluzole	31-33	superoxide dismutase 1	Homo sapiens	111-116
35491161-0	2022	Riluzole Promotes Neurite Growth in Rats after Spinal Cord Injury through the GSK-3beta/CRMP-2 Pathway.	Riluzole	0-8	glycogen synthase kinase 3 alpha	Rattus norvegicus	78-87
35491161-0	2022	Riluzole Promotes Neurite Growth in Rats after Spinal Cord Injury through the GSK-3beta/CRMP-2 Pathway.	Riluzole	0-8	dihydropyrimidinase-like 2	Rattus norvegicus	88-94
35491161-3	2022	This study verified the effectiveness of riluzole and speculated that a riluzole-afforded protection mechanism may be associated with the glycogen synthase kinase-3 beta (GSK-3beta)/collapsin response mediator protein-2 (CRMP-2) pathway in rats after spinal cord injury.	Riluzole	72-80	glycogen synthase kinase 3 beta	Rattus norvegicus	138-169
35491161-3	2022	This study verified the effectiveness of riluzole and speculated that a riluzole-afforded protection mechanism may be associated with the glycogen synthase kinase-3 beta (GSK-3beta)/collapsin response mediator protein-2 (CRMP-2) pathway in rats after spinal cord injury.	Riluzole	72-80	glycogen synthase kinase 3 alpha	Rattus norvegicus	171-180
35491161-3	2022	This study verified the effectiveness of riluzole and speculated that a riluzole-afforded protection mechanism may be associated with the glycogen synthase kinase-3 beta (GSK-3beta)/collapsin response mediator protein-2 (CRMP-2) pathway in rats after spinal cord injury.	Riluzole	72-80	dihydropyrimidinase-like 2	Rattus norvegicus	182-219
35491161-3	2022	This study verified the effectiveness of riluzole and speculated that a riluzole-afforded protection mechanism may be associated with the glycogen synthase kinase-3 beta (GSK-3beta)/collapsin response mediator protein-2 (CRMP-2) pathway in rats after spinal cord injury.	Riluzole	72-80	dihydropyrimidinase-like 2	Rattus norvegicus	221-227
35491161-7	2022	Furthermore, Western blotting and immunofluorescence data revealed that the expression levels of GSK-3beta and phosphorylated-GSK-3beta were lower in riluzole-treated SCI rats compared with vehicle-treated rats.	Riluzole	150-158	glycogen synthase kinase 3 alpha	Rattus norvegicus	97-106
35491161-7	2022	Furthermore, Western blotting and immunofluorescence data revealed that the expression levels of GSK-3beta and phosphorylated-GSK-3beta were lower in riluzole-treated SCI rats compared with vehicle-treated rats.	Riluzole	150-158	glycogen synthase kinase 3 alpha	Rattus norvegicus	126-135
35491161-8	2022	We next detected the expression CRMP-2 and phosphorylated CRMP-2 and found that the expression of CRMP-2 showed no difference between the riluzole-treated and vehicle-treated groups; however, administration of riluzole downregulated phosphorylated CRMP-2 expression.	Riluzole	210-218	dihydropyrimidinase-like 2	Rattus norvegicus	32-38
35491161-8	2022	We next detected the expression CRMP-2 and phosphorylated CRMP-2 and found that the expression of CRMP-2 showed no difference between the riluzole-treated and vehicle-treated groups; however, administration of riluzole downregulated phosphorylated CRMP-2 expression.	Riluzole	210-218	dihydropyrimidinase-like 2	Rattus norvegicus	58-64
35491161-8	2022	We next detected the expression CRMP-2 and phosphorylated CRMP-2 and found that the expression of CRMP-2 showed no difference between the riluzole-treated and vehicle-treated groups; however, administration of riluzole downregulated phosphorylated CRMP-2 expression.	Riluzole	210-218	dihydropyrimidinase-like 2	Rattus norvegicus	98-104
35491161-8	2022	We next detected the expression CRMP-2 and phosphorylated CRMP-2 and found that the expression of CRMP-2 showed no difference between the riluzole-treated and vehicle-treated groups; however, administration of riluzole downregulated phosphorylated CRMP-2 expression.	Riluzole	210-218	dihydropyrimidinase-like 2	Rattus norvegicus	248-254
35491161-9	2022	The current findings suggest that after SCI, administration of riluzole promotes neurological functional restoration, which may be associated, in part, with its activation of the GSK-3beta/CRMP-2 signaling pathway.	Riluzole	63-71	glycogen synthase kinase 3 alpha	Rattus norvegicus	179-188
35491161-9	2022	The current findings suggest that after SCI, administration of riluzole promotes neurological functional restoration, which may be associated, in part, with its activation of the GSK-3beta/CRMP-2 signaling pathway.	Riluzole	63-71	dihydropyrimidinase-like 2	Rattus norvegicus	189-195